t73222_10q.htm

3.17. Certain Payments

None of Seller, nor any of Seller’s directors, officers, agents or employees, or any other Person associated with or acting for or on behalf of Seller with respect to the Acquired Assets or the Business, has (i) made any contribution, gift, bribe, rebate, payoff, influence payment, kickback or other payment to any Person, private or public, regardless of form, whether in money, property or services (A) to improperly obtain favorable treatment in securing business, (B) to improperly pay for favorable treatment for business secured, (C) to improperly obtain special concessions or for special concessions already obtained, for or in respect of Seller, or (D) in violation of any Legal Requirement, or (ii) established or maintained any fund or asset that has not been recorded in the Business Records.

3.18. Relationships with Related Persons

No Related Person of Seller has or has had, any interest in any property (whether real, personal or mixed and whether tangible or intangible) used in or pertaining to any Acquired Asset or Assumed Liability. No Related Person of Seller owns or has owned (of record or as a beneficial owner) an equity interest or any other financial or profit interest in, a Person that has had business dealings or a material financial interest in any transaction with the Business.

3.19. Product Warranty and Liability

Schedule 3.19 sets forth (i) the standard warranties and return policies (by product) provided by Seller in connection with the Business and (ii) a summary of product returns by any Core Customer (excluding the return of unused brachytherapy seeds and related products and materials in the Ordinary Course of Business) for 2010 and 2011 year-to-date describing the reason for each return and whether it was covered by warranty. Except as set forth in Schedule 3.19, no Core Customer has been provided warranties or return rights that vary from the standard warranties and return policies described on Schedule 3.19. Except as set forth in Schedule 3.19, there are no claims pending against Seller for the violation of any product warranties given by Seller with respect to products sold by the Business and, to the Knowledge of Seller, there is no basis for any such claim. Seller has not granted any warranty terms to customers of the Business that are outside of the Ordinary Course of Business or outside of prevailing market conditions and customer requirements.

3.20. Brokers or Finders

Except as set forth in Schedule 3.20, Seller has not incurred any obligation or Liability, contingent or otherwise, for brokerage or finders’ fees or agents’ commissions or other similar payment in connection with this Agreement or the Contemplated Transactions.

4.	REPRESENTATIONS AND WARRANTIES OF PURCHASER

Purchaser represents and warrants to Seller as follows:

4.1. Organization and Good Standing

Purchaser is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.

4.2. Authority; No Conflict

(a) The Transaction Documents constitute the legal, valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms (subject to the effects of bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other Legal Requirements now or hereafter in effect relating to creditors’ rights generally and general principles of equity). Purchaser has the right, power and authority to execute and deliver the Transaction Documents, and to perform its obligations under such Transaction Documents.

(b) Neither the execution and delivery of the Transaction Documents by Purchaser, nor the consummation or performance of any of the Contemplated Transactions by Purchaser, will give any Person the right to prevent, delay or otherwise interfere with any of the Contemplated Transactions pursuant to: (i) any provision of the Organizational Documents of Purchaser; (ii) any resolution adopted by the board of directors of Purchaser; or (iii) any Legal Requirement or Order to which Purchaser may be subject. Other than Consents received as of the Closing Date, Purchaser is not required to obtain any Consent from any Person in connection with the execution and delivery of this Agreement or the consummation of any of the Contemplated Transactions.

4.3. Certain Proceedings

There is no pending Proceeding that has been commenced against Purchaser that challenges, or may have the effect of preventing, delaying, making illegal or otherwise interfering with, any of the Contemplated Transactions. To the Knowledge of Purchaser, no such Proceeding has been threatened.

4.4. Brokers or Finders

Neither Purchaser nor any of Purchaser’s directors, officers and agents, has incurred any obligation or liability, contingent or otherwise, for brokerage or finders’ fees or agents’ commissions or other similar payment in connection with this Agreement other than the fees that may be payable by Purchaser to VRA Partners.

5.	PRE-CLOSING COVENANTS

5.1. Access and Investigation

Between the date of this Agreement and the Closing Date, Seller will, and will cause its Representatives to, (i) afford Purchaser and its Representatives full and free access to the Acquired Assets, the Assumed Liabilities, the Business, the payroll information, properties, contracts, books and records, and other documents and data of or pertaining to the Business, (ii) furnish Purchaser and its Representatives with copies of all such contracts, books and records, and other existing documents and data relating to the Business and the Acquired Assets as Purchaser and its Representatives may reasonably request, and (iii) furnish Purchaser and its Representatives with such additional financial, payroll, operating and other data and information relating to the Business and the Acquired Assets as Purchaser and its Representatives may reasonably request. Seller acknowledges and agrees that from and after the Closing, Purchaser will have the right to possession of all documents, books, records (including non-income Tax records), agreements and financial data of any sort relating to the Acquired Assets, the Assumed Liabilities and the Business (other than Excluded Assets and materials constituting attorney-client privileged materials or materials subject to privacy obligations not waivable by Seller); provided, however, that following the Closing, Seller shall have the right to obtain access to such documents, books, records (including Tax records), agreements and financial data to the extent related to the period prior to the Closing and make photocopies thereof for a proper purpose, such as in connection with the preparation of its Tax Returns.

5.2. Operation of the Business

Between the date of this Agreement and the Closing Date, Seller will: (i) operate the Business (or otherwise conduct the Business) only in the Ordinary Course of Business; (ii) use its Best Efforts to maintain the relations and goodwill with suppliers, creditors, employees, agents, customers and others having business relationships with the Business; (iii) confer with Purchaser concerning operational matters of the Business of a material nature; (iv) not enter into any material Contract relating to the Business (for purposes hereof, the word “material” shall refer to any contract or commitment which, if it had been entered into prior to execution of this Agreement, would have been required to be disclosed in Section 3.12); and (v) otherwise report periodically to Purchaser concerning the status of the Business, the Acquired Assets and the Assumed Liabilities.

5.3. Negative Covenant

Except as otherwise expressly permitted by this Agreement, between the date of this Agreement and the Closing Date, Seller will not, without the prior consent of Purchaser, take any affirmative action, or fail to take any reasonable action within its control, as a result of which any of the changes or events listed in Section 3.11 could occur.

5.4. Required Approvals

As promptly as practicable after the date of this Agreement, Seller will use its Best Efforts to receive all necessary Consents (i) of each Governmental Body from which Consent may be required to consummate the Contemplated Transactions, (ii) of all other Persons whose consent to the consummation of the Contemplated Transactions may be required, or who may have a Security Interest in any of the Acquired Assets, and (iii) with respect to each matter, and from each Person, specifically identified in Schedule 5.4 (collectively, the “Required Approvals”). Between the date of this Agreement and the Closing Date, each Party will cooperate with each other Party with respect to all filings that each such Party elects to make or is required by Legal Requirements to make in connection with the Contemplated Transactions.

5.5. Release of Security Interests

Seller will take all necessary action to cause the release of all Security Interests on the Acquired Assets prior to or simultaneous with the Closing.

5.6. No Negotiation

Between the date of this Agreement and the Closing Date, or until such time, if any, as this Agreement is terminated pursuant to Section 9, Seller will not, and will not permit any of its Representatives to, directly or indirectly, (i) solicit, initiate or encourage the submission or proposal of any offers, or accept any offers, or enter into a confidentiality agreement, letter of intent or purchase agreement or other similar agreement with any Person other than Purchaser, with respect to the acquisition of equity interests of Seller that would result in a change in control of Seller, or a merger, consolidation, business combination that would result in a change in control of Seller, or a sale of all or substantially all of the assets of Seller or of any of the Acquired Assets, or any similar extraordinary transaction with respect to the Business (an “Acquisition Proposal”) or (ii) participate in any discussions or negotiations regarding, or furnish to any Person other than Purchaser any information with respect to, or otherwise cooperate in any way with or assist, facilitate or encourage any Acquisition Proposal by any Person other than Purchaser. Seller agrees to notify Purchaser (within two (2) Business Days) of all relevant terms of any proposals by any other Person (including the identity of any such Person) to do any of the foregoing which Seller, or any of its Representatives, may receive relating to any of such matters and, if such inquiry or proposal is in writing, Seller will deliver to Purchaser a copy of such inquiry or proposal. Seller will terminate simultaneously with the execution and delivery of this Agreement any discussions regarding an Acquisition Proposal that may be ongoing as of such time.

5.7. Best Efforts

Between the date of this Agreement and the Closing Date, each of the Parties will use their respective Best Efforts to cause the conditions in Section 7 and Section 8 to be satisfied and to preserve intact the Business and the Acquired Assets.

5.8. Assignment of Interests in Acquired Assets

Nothing in this Agreement shall be deemed to constitute or require an assignment or an attempt to assign any of the Acquired Assets if the attempted assignment without the Consent of a third party would adversely affect in any way the rights of Purchaser. If any such Consent shall not have been obtained at or prior to the Closing, or the attempted transfer or assignment of any of the Acquired Assets, would have an adverse effect on Purchaser, then, at Purchaser’s option, Seller will cooperate with Purchaser (at Seller’s expense) in any reasonable arrangement designed to provide for Purchaser the rights and benefits of such Acquired Assets, including, enforcing for the benefit of Purchaser any or all rights of Seller against any other party arising out of the breach or cancellation by such other party, while permitting Purchaser the possession and use of such Acquired Assets for Purchaser’s account as if such Acquired Assets had been so transferred, assigned and delivered, or otherwise. Following the Closing, pending the obtaining of such Consents, Purchaser will continue performance of any remaining unfulfilled obligations of Seller that would have constituted Assumed Liabilities had the Acquired Assets relating or subject thereto been assigned, in the same manner as though the same were subcontracted to Purchaser on the same terms and conditions as contained in the agreements.

5.9. Notification of Certain Events

Seller shall give prompt notice to Purchaser of (i) any fact, event or circumstance known to Seller that individually or taken together with all other facts, events and circumstances known to Seller, is reasonably likely to have, individually or in the aggregate, a Material Adverse Effect, or that would cause or constitute a breach of any of Seller’s representations, warranties, covenants or agreements contained herein, (ii) any fact, event or circumstance known to Seller that individually or taken together with all other facts, events and circumstances known to Seller, has had or is reasonably likely to result in the failure of any condition precedent to the Purchaser’s obligations contained herein, and (iii) any notice or other communication from any Governmental Entity or other Person in connection with the Contemplated Transactions; provided, however, that the delivery of any notice pursuant to this Section 5.9 shall not limit or otherwise affect any remedies available to Purchaser or prevent or cure any misrepresentations, breach of warranty or breach of covenant by Seller.

5.10. Supplements to Disclosure Schedules

From time to time up to the Closing Date, Seller shall promptly supplement the Disclosure Schedules with respect to any matter (i) first existing or occurring after the date hereof which, if existing or occurring at or prior to such date, would have been required to be set forth in any of the Disclosure Schedules to this Agreement, or (ii) that is necessary to correct any information in such Disclosure Schedule that is inaccurate on account thereof. No supplement to the Disclosure Schedules shall have any effect for purposes of determining satisfaction of the conditions set forth in Section 7 of this Agreement unless such supplement is accepted by Purchaser in writing in its sole discretion. For purposes of determining whether there is any misrepresentation or breach of warranty, covenant or agreement by Seller hereunder, the Disclosure Schedules delivered by Seller shall be deemed to include only the information contained therein on the date of this Agreement as such Disclosure Schedules may be supplemented prior to the Closing in writing with Purchaser’s written consent, which consent may be withheld by Purchaser in its sole discretion.

5.11. Employees

Purchaser has no obligation to offer employment to any Person employed by Seller in the Business and Purchaser is not assuming any Liability with respect to (i) any employment, deferred compensation or similar Contract with any of Seller’s employees, (ii) any severance obligation to any of employee of Seller, or (iii) any Company Plan. Further, the Parties agree that Seller, at its sole cost and expense, shall be solely responsible for any continuation coverage required under COBRA (including continuation coverage resulting from any transactions prior to or contemplated by this Agreement). Seller shall release any employee or former employee who accepts an offer of employment from Purchaser from any restrictive covenant to which any such employee may be subject, including covenants imposing non-competition, non-solicitation and non-disclosure obligations on such employee.

5.12. Meetings with Customers and Suppliers

Between the date of this Agreement and the Closing Date, Seller shall permit Purchaser and its Representatives to discuss and meet and shall cooperate in such discussions and meetings, upon the reasonable request of Purchaser, with HealthTrust Purchasing Group, L.P. (“HPG”) to discuss the Contemplated Transaction and confirm the willingness of HPG to (i) continue to be a customer of the Business via assignment and assumption of the Purchase Agreement by and between Seller and HPG, dated February 1, 2010 as of the Closing Date and (ii) work cooperatively with Purchaser to [***]1 prior to the Closing Date. To the extent Purchaser concludes that a similar meeting may be appropriate to discuss the assignment and assumption of any other Acquired Contract that is material to the Business, Seller shall similarly permit such meeting and cooperate with respect thereto. An appropriate Representative of Seller may accompany Purchaser and Purchaser’s Representatives on such visits and may participate with Purchaser and Purchaser’s Representatives in any such discussions. Seller will cooperate with Purchaser, as reasonably requested by Purchaser, in the preparation of a presentation to any Persons with respect to the Contemplated Transactions.

6.	POST-CLOSING COVENANTS

6.1. Litigation Support

Following the Closing, in the event and for so long as any Party actively is contesting or defending against any Proceeding in connection with (i) the Contemplated Transactions or (ii) any fact, situation, circumstance, status, condition, activity, practice, plan, occurrence, event, incident, action, failure to act or transaction on or prior to the Closing Date involving any Party, the other Party will reasonably cooperate with the contesting or defending Party and its counsel in the contest or defense, make available its personnel, and provide such testimony and access to its books and records as shall be necessary in connection with the contest or defense, all at the sole cost and expense of the contesting or defending Party (unless the contesting or defending Party is entitled to indemnification therefore under Section 10 below).

6.2. Transition

Seller will use its Best Efforts not to take any action that is designed or intended to have the effect of discouraging any lessor, licensor, supplier, employee or other business associate of Seller with respect to the Business from maintaining the same business relationships with Purchaser with respect to the Business after the Closing as it maintained with the Seller with respect to the Business prior to the Closing.

6.3. Tax Matters

(a) With respect to the Contemplated Transactions, the Parties will provide each other with such cooperation and information as any of them may reasonably require in connection with the filing of any Tax Return, the determination of a liability for Taxes or a right to a refund for Taxes, or the preparation for litigation or investigation of any claim for Taxes or a right to a refund for Taxes. Any information obtained under this provision shall be kept confidential by the Parties, except as may be necessary in connection with the filing of such Tax Returns.

1 EXPLANATORY NOTE: “[***]” indicates the portion of this document that has been omitted and separately filed with the Securities and Exchange Commission pursuant to a request for confidential treatment.

(b) All sales, transfer and similar Taxes arising from or associated with the Contemplated Transactions, whether levied on Purchaser or Seller, shall be paid by Seller.

6.4. Restrictive Covenants

(a) From and after the Closing, Seller and each of the shareholders of Seller who are a Party to this Agreement for the limited purpose of providing the undertakings contained in this Section 6.4 (the “Subject Shareholders”), will treat and hold as confidential all of the Confidential Information and the terms and conditions contained in the Transaction Documents and in respect to the Contemplated Transactions (except disclosures of such terms and conditions to Seller’s Representatives having a need to know, and to Seller’s senior secured lender), refrain from using any of the Confidential Information and deliver promptly to Purchaser or destroy, at the request and option of Purchaser, all tangible embodiments (and all copies) of the Confidential Information that are in its possession. In the event that Seller, any of Seller’s Representatives or any Subject Shareholder is requested or required (by oral question or request for information or documents in any Proceeding) to disclose any Confidential Information or the terms and conditions contained in this Agreement and in respect to the Contemplated Transactions, Seller or such Subject Shareholder will notify Purchaser promptly of the request or requirement so that Purchaser may seek an appropriate protective order or waive compliance with the provisions of this Section 6.4. If, in the absence of a protective order or the receipt of a waiver hereunder, Seller, Seller’s Representative or any Subject Shareholder is, on the advice of counsel, compelled to disclose any Confidential Information or the terms and conditions contained in this Agreement and in respect of the Contemplated Transactions, to any tribunal or else stand liable for contempt, Seller, such Representative or such Subject Shareholder, as applicable, may disclose the Confidential Information or the terms and conditions contained in this Agreement and in respect of the Contemplated Transactions, as the case may be, to the tribunal; provided, however, that Seller, such Representative or such Subject Shareholder, as applicable, shall use its Best Efforts to obtain, at the reasonable request of Purchaser and at the sole expense of Purchaser, an order or other assurance that confidential treatment will be accorded to such portion of the Confidential Information or the terms and conditions contained in this Agreement in respect of the Contemplated Transactions, as the case may be, required to be disclosed as Purchaser shall designate.

(b) Seller and each Subject Shareholder expressly covenants and agrees that, for a period of five years from and after the Closing Date, Seller and each Subject Shareholder will not, within the Territory, either directly or indirectly, on its or their own behalf or in the service or on behalf of others, engage in or provide managerial, supervisory, sales, marketing or consulting services or assistance to, or own a beneficial interest in, any Competing Business (or any material aspect thereof).

(c) For a period of five years from and after the Closing Date, Seller and each Subject Shareholder will not, directly or indirectly, for itself or for any other Person (other than the Purchaser or any of its Affiliates), call on or solicit any of the customers or business partners of Purchaser or its Affiliates for the purpose of competing with the Business, nor shall Seller or any Subject Shareholder make known to any Person other than Purchaser the names and addresses of such customers or business partners for the purpose of competing with the Business or any information relating in any manner to the trade or business relationships of the Business with such customers or business partners.

(d) For a period of five years from and after the Closing Date, Seller and each of the Subject Shareholders will not, directly or indirectly, for itself or for any other Person (other than Purchaser or its Affiliates), recruit or hire away or attempt to recruit or hire away, on any of their behalves or on behalf of any other Person, any employee, consultant, independent contractor, manager or director of Purchaser associated with the Business.

(e) Seller and each of the Subject Shareholders acknowledges that Purchaser has agreed to enter into this Agreement based, in part, on the agreement of Seller and each Subject Shareholder to the restrictive covenants contained in this Section 6.4. Seller and each Subject Shareholder expressly acknowledge and agree that the covenants contained in this Section 6.4 are reasonable in scope and duration.

(f) If any covenant in this Section 6.4 is held to be unreasonable, arbitrary or against public policy, such covenant will be considered to be divisible with respect to scope, time and geographic area, and such lesser scope, time or geographic area, or all of them, as a court of competent jurisdiction may determine to be reasonable, not arbitrary, and not against public policy, will be effective, binding and enforceable against Seller and each Subject Shareholder.

(g) Seller and each Subject Shareholder expressly acknowledge and agree that money damages may not be an adequate remedy for any breach or threatened breach of the provisions of this Section 6.4 and that Purchaser may in its sole discretion apply to any court of law or equity of competent jurisdiction for specific performance and/or injunctive relief to enforce or prevent any violations or threatened violations of the provisions of this Section 6.4.

(h) Seller and each Subject Shareholder each agree to refrain from taking any action (including, but not limited to, sales and marketing activities) to influence or attempt to influence any of the Core Customers to purchase, or cause to be purchased, any goods or services from Purchaser during the period between the Closing Date and the last day of the eighteenth month immediately following the month in which the Closing Date occurs (the “Earn-Out Period”). Further, Seller shall not make any payment or distribution to any individual or entity in respect of any action taken by such person (including, but not limited to, sales and marketing activities) to influence or attempt to influence any of the Core Customers to purchase, or cause to be purchased, any goods or services from Purchaser during the Earn-Out Period. The foregoing is not intended to prohibit Seller or any Subject Shareholder from providing assistance and information to Purchaser (e.g., contact information, customer histories, etc.) that may be helpful to Purchaser in marketing to Core Customers, so long as Seller and any Subject Shareholder do not contact Customers themselves in connection with such assistance.

6.5. Release

(a) Anything contained herein to the contrary notwithstanding, in consideration for the Purchase Price, as of and following the Closing Date, Seller, as seller of the Acquired Assets and assignor of the Assumed Liabilities hereunder, on its own behalf and on behalf of any of its Affiliates, shareholders, creditors and other parties in interest (collectively, the “Seller Releasing Parties”), knowingly, voluntarily and unconditionally releases, forever discharges, and covenants not to sue Purchaser or any of Purchaser’s Affiliates, predecessors, successors, parents, subsidiaries and current, former and future Representatives, from and for any and all claims, causes of action, demands, suits, debts, obligations, liabilities, damages, losses, costs, and expenses (including attorneys’ fees) of every kind or nature whatsoever, known or unknown, asserted or unasserted, accrued or unaccrued, liquidated or unliquidated, due or to become due, actual or potential, suspected or unsuspected, fixed or contingent, that Seller or any Seller Releasing Party has or may have, now or in the future, arising out of, relating to or resulting from any right to payments or other compensation, act of commission or omission, errors, negligence, strict liability, breach of contract, right to indemnification (whether pursuant to an entity’s charter documents or otherwise), tort, violations of law, matter or cause whatsoever from the beginning of time to the Closing Date, including any claim or cause of action based on any theory of successor liability; provided, however, that such release shall not cover any claims against Purchaser or arising as a result of any breach by Purchaser of a specific obligation under this Agreement. In the event of any suit, claim, demand or other action brought against Purchaser or any of its Affiliates by a Seller Releasing Party, Purchaser or such Affiliate may file a copy of this release with Purchaser’s or such Affiliate’s motion to dismiss, request for summary judgment or motion seeking similar relief and no Seller Releasing Party may object thereto.

(b) Anything contained herein to the contrary notwithstanding, in consideration for the closing of the Contemplated Transactions, as of and following the Closing Date, Purchaser, as purchaser of the Acquired Assets and assignee of the Assumed Liabilities hereunder, on its own behalf and on behalf of any of its Affiliates, shareholders, creditors and other parties in interest (collectively, the “Purchaser Releasing Parties”), knowingly, voluntarily and unconditionally releases, forever discharges, and covenants not to sue Seller or any of Seller’s Affiliates, predecessors, successors, parents, subsidiaries and current, former and future Representatives, from and for any and all claims, causes of action, demands, suits, debts, obligations, liabilities, damages, losses, costs, and expenses (including attorneys’ fees) of every kind or nature whatsoever, known or unknown, asserted or unasserted, accrued or unaccrued, liquidated or unliquidated, due or to become due, actual or potential, suspected or unsuspected, fixed or contingent, that Purchaser or any Purchaser Releasing Party has or may have, now or in the future, arising out of, relating to or resulting from any right to payments or other compensation, act of commission or omission, errors, negligence, strict liability, breach of contract, right to indemnification (whether pursuant to an entity’s charter documents or otherwise), tort, violations of law, matter or cause whatsoever from the beginning of time to the Closing Date, including any claim or cause of action based on any theory of successor liability; provided, however, that such release shall not cover any claims against Seller or arising as a result of any breach by Seller of a specific obligation under this Agreement. In the event of any suit, claim, demand or other action brought against Seller or any of its Affiliates by a Purchaser Releasing Party, Seller or such Affiliate may file a copy of this release with Seller’s or such Affiliate’s motion to dismiss, request for summary judgment or motion seeking similar relief and no Purchaser Releasing Party may object thereto.

6.6. Sufficiency of Working Capital

At all times during the term of the Temporary Manufacturing and Supply Agreement, Seller shall maintain a level of working capital (consisting of cash, cash equivalents and inventory) as shall be necessary or desirable in the judgment of Seller’s board of directors to enable Seller to meet and discharge its obligations arising pursuant to the Temporary Supply Agreement including, without limitation, and for the avoidance of doubt, maintaining an adequate level of inventory of the necessary products, materials and supplies, and maintaining an adequate workforce, as shall be reasonably necessary to fulfill Purchaser’s orders for products on or before each scheduled delivery date. To facilitate Seller’s maintenance of sufficient working capital, Purchaser will pay all invoices for product purchased pursuant to the Temporary Manufacturing and Supply Agreement and delivered on or before the scheduled delivery date within fifteen (15) Business Days following the delivery of each such order by wire transfer of immediately available funds to an account designated by Seller.

6.7. Deferred Purchased Intellectual Property.

(a) Seller shall at Seller’s expense diligently maintain all of the Deferred Purchased Intellectual Property in effect to and through the effective date of transfer of title thereto to Purchaser and during such time shall pay all legal costs, filing fees, renewal fees, etc. necessary to prosecute the completion of any registrations thereof currently underway or to maintain in effect any registrations thereof currently in existence or hereafter obtained. In order to avoid missed deadlines arising out of the transition of ownership, unless otherwise agreed by Purchaser in any given case Seller shall prepare and file prior to the due date of the Final Earn-Out Payment, all documents that are due to be filed with any patent or trademark office or agency with respect to Deferred Purchased Intellectual Property either prior to or within thirty (30) days after the due date of the Final Earn-Out Payment. Prior to the due date of the Final Earn-Out Payment, Seller shall furnish Purchaser with all reasonably requested information and cooperation with respect to the prosecution, maintenance and final transfer of Deferred Purchased Intellectual Property, including furnishing Purchaser upon request with copies of any past, current or prospective filings, office actions, written communications with patent or trademark offices or agencies, written communications with intellectual property counsel, schedules of upcoming filing deadlines, etc. regarding Deferred Purchased Intellectual Property; shall permit Purchaser to confer with Seller’s intellectual property counsel regarding the same; and shall respond to any office actions or similar proceedings as Purchaser shall reasonably request. For avoidance of doubt, Seller’s obligations under Section 11.4 include the obligation to execute and deliver documents further confirming the transfer of the Deferred Purchased Intellectual Property form suitable for filing and recording in each relevant jurisdiction.

(b) Seller shall not sell, convey, hypothecate, grant or suffer to exist a Security Interest in, any of the Deferred Purchased Intellectual Property, and shall promptly obtain the release of any Security Interest therein that may arise by operation of law or otherwise; provided that the Security Interest of Seller’s senior secured lender shall not constitute a breach of this covenant if such Security Interest has been subordinated to Purchaser’s rights as described in Section 7.3.

7.	CONDITIONS PRECEDENT TO PURCHASER’S OBLIGATION TO CLOSE

Purchaser’s obligation to effect the Closing and to take the other actions required to be taken by Purchaser at the Closing is subject to the satisfaction, at or prior to the Closing, of each of the following conditions (any of which may be waived by Purchaser, in whole or in part):

7.1. Accuracy of Representations; Performance by Seller

(a) The representations and warranties of Seller in this Agreement and the Disclosure Schedules (without giving effect to any updates, supplements or additions to the Disclosure Schedules delivered hereunder except for any such updates supplements or additions that have been accepted by Purchaser pursuant to Section 5.10 hereof) and in any of the Transaction Documents shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as of each such date (except for those representations and warranties that address matters only as of a particular date, which representations and warranties shall be true and correct only as of such date).

(b) At or prior to the Closing, Seller shall have fully performed or complied with the covenants and obligations that Seller is required to perform or comply with pursuant to this Agreement and each of the Transaction Documents.

7.2. Additional Documents

Seller must have delivered each of the following additional executed documents:

(a) the Temporary Manufacturing and Supply Agreement;

(b) the Bill of Sale;

(d) the Nonexclusive IP License described in the definition of Acquired Intellectual Property;

(e) the Deferred Purchased IP License described in the definition of Acquired Intellectual Property;

(f) such other instruments and documents as may be reasonably requested by Purchaser to complete the transfer of the Acquired Assets and the Assumed Liabilities, each in form and substance satisfactory to Purchaser;

(g) a certificate executed by Seller confirming that each of the representations and warranties of Seller in this Agreement and in the Transaction Documents were accurate in all respects as of the date of this Agreement and are accurate as of the Closing Date as if made on the Closing Date;

(h) a certificate executed by Seller certifying that the conditions set forth in this Section 7 have been satisfied; and

(i) a certificate of an officer of Seller as to the incumbency of its officers, certifying and attaching a copy of a certificate evidencing the organization and good standing of the Seller as of a date no earlier than five (5) Business Days prior to the Closing Date, and certifying and attaching copies of the resolutions adopted by the board of directors and shareholders of Seller with respect to the Contemplated Transactions.

7.3. Release of Security Interests; Subordination and Consent to Transfer

Seller shall have satisfied all obligations owed to its creditors necessary to obtain a complete release of the Acquired Assets from all Security Interests, and otherwise permit Purchaser to obtain the Nonexclusive IP License and the Deferred Purchased IP License free and clear of any security interests, and marketable title to the other Acquired Assets or, at Purchaser’s option, shall have obtained and provided to Purchaser releases from such creditors, in form and substance satisfactory to Purchaser, which contain release information with respect to the requirements for the release of all such Security Interests on and as of the Closing Date and an agreement by such creditors to execute and record releases of the Acquired Assets upon compliance therewith. With respect to the Nonexclusive IP License and the Deferred Purchased IP License, Seller shall have obtained from its senior secured lender, for the express benefit of Purchaser, a written subordination agreement, subordinating the lender’s Security Interest in the Intellectual Property licensed thereunder, to Purchaser’s rights as licensee under the licenses, such that Purchaser’s rights as licensee shall survive unchanged notwithstanding any foreclosure or other exercise of the lender’s rights with respect to such Security Interests. Furthermore, Seller shall have obtained a written undertaking of such lender, for the express benefit of Purchaser, to release its Security Interest in the Deferred Purchased Intellectual Property upon receipt of the Final Earn-Out Payment by Seller (or by the lender, if the lender is then entitled to receive such payment) and to convey to Purchaser any other interest in the Deferred Purchased Intellectual Property which the lender may have at the time the Final Earn-Out Payment is received, whether such interest in the Deferred Purchased Intellectual Property was obtained via foreclosure, by transfer or acceptance in lieu of foreclosure, or otherwise.

7.4. No Proceedings

No Proceeding shall be threatened or commenced (i) involving any challenge to, or seeking damages or other relief in connection with, any of the Contemplated Transactions, or (ii) that may have the effect of preventing, delaying or making illegal any of the Contemplated Transactions.

7.5. No Claim Regarding Ownership or Sale Proceeds

There must not have been made or threatened by any Person any claim asserting that such Person (i) has any interest in or right to acquire the Acquired Assets or the Assumed Liabilities, or (ii) is entitled to all or any portion of the Purchase Price.

7.6. No Material Adverse Effect

There must not have been any Material Adverse Effect, and no event shall have occurred or circumstance exist that would reasonably be expected to result in such a Material Adverse Effect.

7.7. Required Consents

All Required Approvals listed in Schedule 5.4 shall have been obtained and shall be in full force and effect.

7.8. No Prohibition

Neither the consummation nor the performance of any of the Contemplated Transactions will, directly or indirectly (with or without notice or lapse of time), materially contravene or conflict with, or result in a material violation of, or cause Purchaser or any Person affiliated with Purchaser to suffer any material adverse consequence under, (i) any applicable Legal Requirement or Order, or (ii) any Legal Requirement or Order that has been published, introduced, or otherwise formally proposed by or before any Governmental Body.

7.9. Due Diligence

Representatives of Purchaser shall have completed the due diligence review of the operations, condition (financial and other), prospects, assets and liabilities of, and other matters related to, Seller and the Business to Purchaser’s satisfaction.

7.10. Assignment of Contracts

Representatives of Purchaser shall have met with Representatives of HPG to discuss the Contemplated Transaction and confirmed the willingness of HPG to (i) continue to be a customer of the Business following the Closing Date and (ii) work cooperatively with Seller and Purchaser to [***] prior to the Closing Date. Seller shall have obtained the necessary consents to the assignment to Purchaser of the Purchasing Agreement by and between Seller and HPG, dated February 1, 2010, and shall have [***].

8.	CONDITIONS PRECEDENT TO THE SELLER’S OBLIGATION TO CLOSE

Seller’s obligation to effect the Closing and to take the other actions required to be taken by Seller at the Closing is subject to the satisfaction, at or prior to the Closing, of each of the following conditions (any of which may be waived by Seller, in whole or in part):

8.1. Accuracy of Representations; Purchaser’s Performance

(a) The representations and warranties of Purchaser in this Agreement and in the Transaction Documents shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as of each such date (except for those representations and warranties that address matters only as of a particular date, which representations and warranties shall be true and correct only as of such date).

(b) At or prior to the Closing, Purchaser shall have fully performed or complied with the covenants and obligations that Purchaser is required to perform or comply with pursuant to this Agreement.

8.2. Additional Documents

Purchaser must have delivered each of the following additional executed documents to Seller:

(a) the Temporary Manufacturing and Supply Agreement;

(b) the Bill of Sale;

(d) a certificate executed by Purchaser confirming that each of the representations and warranties of Purchaser in this Agreement and in the Transaction Documents were accurate in all respects as of the date of this Agreement and are accurate in all respects as of the Closing Date as if made on the Closing Date;

(e) a certificate executed by Purchaser certifying that the conditions set forth in Section 8 have been satisfied; and

(f) a certificate of the Secretary of Purchaser as to the incumbency of its officers and certifying and attaching a copy of the resolutions adopted by the board of directors of Purchaser with respect to the Contemplated Transactions.

8.3. No Injunction

There must not be in effect any Legal Requirement or any injunction or other Order that prohibits the Contemplated Transactions.

9. TERMINATION

9.1. Termination Events

This Agreement may, by notice given prior to or at the Closing, be terminated:

(a) by Purchaser, on the one hand, or Seller, on the other hand, if a material breach of any provision of this Agreement has been committed by the other Party and such breach has not been waived or cured within fifteen (15) days of such material breach, and the Party seeking to terminate is not in breach of any provision of this Agreement;

(b) (i) by Purchaser if any of the conditions in Section 7 has not been satisfied as of the Closing Date or if satisfaction of such a condition is or becomes impossible (other than through the failure of Purchaser to comply with its obligations under this Agreement) and Purchaser has not waived such condition on or before the Closing Date; or (ii) by Seller if any of the conditions in Section 8 has not been satisfied as of the Closing Date or if satisfaction of such a condition is or becomes impossible (other than through the failure of Seller to comply with its obligations under this Agreement), and Seller has not waived such condition on or before the Closing Date;

(d) by Purchaser, on the one hand, or Seller, on the other hand, if the Closing has not occurred (other than through the failure of any Party seeking to terminate this Agreement to comply fully with its obligations under this Agreement) on or before March 30, 2012, or such later date as the Parties may agree upon.

9.2. Effect of Termination

Each Party’s right of termination under Section 9.1 is in addition to any other rights it may have under this Agreement or otherwise, and the exercise of a right of termination will not be an election of remedies. If this Agreement is terminated pursuant to Section 9.1, all further obligations of the Parties under this Agreement will terminate, except that the obligations in Section 6.4(a) (as it relates to this Agreement) and Section 11, will survive; provided, however, that if this Agreement is terminated by a Party because of the breach of the Agreement by the other Party or because one or more of the conditions to the terminating Party’s obligations under this Agreement is not satisfied as a result of the other Party’s failure to comply with its obligations under this Agreement, the terminating Party’s right to pursue all legal remedies will survive such termination unimpaired.

10. INDEMNIFICATION; REMEDIES

10.1. Survival

All representations, warranties, covenants and obligations in this Agreement, the other Transaction Documents, the Disclosure Schedules, the certificates delivered pursuant hereto, and any other certificate or document delivered pursuant to the Transaction Documents will survive the Closing. The right to indemnification, payment of Damages or other remedy based on such representations, warranties, covenants and obligations will not be affected by any investigation conducted with respect to, or any Knowledge acquired (or capable of being acquired) at any time, whether before or after the execution and delivery of this Agreement or the Closing Date, with respect to the accuracy or inaccuracy of or compliance with, any such representation, warranty, covenant or obligation, except that Purchaser shall make no claim after the Closing Date with respect to facts disclosed in a Schedule hereto, if Purchaser elects to close the Contemplated Transactions notwithstanding such disclosure. The waiver of any condition based on the accuracy of any representation or warranty, or on the performance of or compliance with any covenant or obligation, will not affect the right to indemnification, payment of Damages or other remedy based on such representations, warranties, covenants and obligations.

10.2. Indemnification and Payment of Damages by Seller

Seller will indemnify, defend and hold harmless Purchaser and Purchaser’s Representatives, shareholders, controlling persons and Affiliates (collectively, the “Purchaser Indemnified Parties”) for, and will pay to the Indemnified Persons the amount of, any loss, Liability, claim, damage (including incidental and consequential damages), expense (including costs of investigation and defense and reasonable attorneys’ fees) or diminution of value, whether or not involving a third-party claim (collectively, “Damages”), arising, directly or indirectly, from or in connection with:

(a) any breach of any representation or warranty made by Seller in this Agreement, the other Transaction Documents, the Disclosure Schedules or any other certificate or document delivered by Seller pursuant to the Transaction Documents;

(b) any breach by Seller of any covenant, agreement or obligation of Seller in any Transaction Document;

(d) any of the Excluded Liabilities;

(e) any Security Interest attached to the Acquired Assets in existence as of the Effective Time;

(f) any Proceeding against Seller or the Business pending as of the Effective Time or arising out of actions or circumstances in existence prior to the Effective Time; or

(g) any Proceeding against Seller, Purchaser or the Business initiated by any Core Customer or any of Seller’s creditors, shareholders or any other Person relating to, arising out of or challenging the Contemplated Transactions.

10.3. Time Limitations; Limitation on Amount

(a) If the Closing occurs, Seller will not have any liability (for indemnification or otherwise) with respect to the Operational Representations, unless on or before the due date of the Third Earn-Out Payment, Purchaser notifies Seller of a claim specifying the factual basis of that claim in reasonable detail to the extent then known by Purchaser; a claim with respect to any Fundamental Representation, or a claim for indemnification or reimbursement based upon any other provision of this Agreement or any Transaction Document, or any covenant or obligation, that is to be performed and complied by Seller after the Closing Date pursuant to any Transaction Documents, may be made at any time.

(b) Seller’s aggregate maximum liability for Damages with respect to a claim for indemnification or reimbursement based on a breach of this Agreement or any of the Transaction Documents shall be limited to and shall not exceed, in the aggregate, (i) with respect to the Operational Representations, the amount of the Closing Cash Payment, and (ii) with respect to the Fundamental Representations, the Purchase Price. No amount shall be payable by Seller unless and until the aggregate amount of all claims for indemnification by the Purchaser Indemnified Parties hereunder shall equal $50,000, in which case the Purchaser Indemnified Parties shall be entitled to seek compensation for the full amount of all such claims. The foregoing limitations shall not apply to any claim based on fraud, intentional misconduct or intentional misrepresentation by Seller in connection with this Agreement or any claim relating to any of the Excluded Liabilities.

(c) The foregoing provisions will not limit the ability of Purchaser to assert any rights or remedies provided for under the Temporary Manufacturing and Supply Agreement which shall be in addition to the remedies provided for under this Agreement.

10.4. Procedure for Indemnification – Third Party Claims

(a) Promptly after receipt by a Purchaser Indemnified Party of notice of the commencement of any Proceeding against it, such Purchaser Indemnified Party will, if a claim is to be made against Seller, give notice to Seller of the commencement of such claim, but the failure to notify Seller will not relieve Seller of any liability that it may have to any Purchaser Indemnified Party, except to the extent that Seller demonstrates that the defense of such action is prejudiced by the Purchaser Indemnified Party’s failure to give such notice.

(b) If any Proceeding is brought against a Purchaser Indemnified Party and it gives notice to Seller of the commencement of such Proceeding, Seller will, unless the claim involves Taxes, be entitled to participate in such Proceeding and, to the extent that it wishes (unless (i) the Purchaser Indemnified Party is also a party to such Proceeding and determines in good faith that joint representation would be inappropriate, or (ii) Seller fails to provide reasonable assurance to the Purchaser Indemnified Party of Seller’s financial capacity to defend such Proceeding and provide indemnification with respect to such Proceeding), to assume the defense of such Proceeding with counsel reasonably satisfactory to the Purchaser Indemnified Party and, after notice from Seller to the Purchaser Indemnified Party of Seller’s election to assume the defense of such Proceeding, Seller will not, as long as it diligently conducts such defense, be liable to the Purchaser Indemnified Party under this Section 10 for any fees of other counsel or any other expenses with respect to the defense of such Proceeding, in each case subsequently incurred by the Purchaser Indemnified Party in connection with the defense of such Proceeding, other than reasonable costs of investigation; provided, however, that if Seller assumes the defense of such Proceeding, Seller shall be deemed to have assumed full responsibility for all Damages resulting from such Proceeding and any subsequent claims or Proceedings relating to or arising from the matters at issue in such Proceeding. Notwithstanding the foregoing, even if Seller assumes the defense of such Proceeding, the Purchaser Indemnified Party will have the right, at its own expense, to participate in, and review and comment on the documentation relating to, the defense of such Proceeding. If Seller assumes the defense of a Proceeding, (i) it will be conclusively established for purposes of this Agreement that the claims made in that Proceeding are within the scope of and subject to indemnification pursuant to this Agreement; (ii) no compromise or settlement of such claims may be effected by Seller without the Purchaser Indemnified Party’s consent; and (iii) the Purchaser Indemnified Party will have no liability with respect to any compromise or settlement of such claims effected without its consent. If notice is given to Seller by a Purchaser Indemnified Party of the commencement of any Proceeding and Seller does not, within ten (10) days after such notice is given, give notice to the Purchaser Indemnified Party of its election to assume the defense of such Proceeding, Seller shall automatically be deemed to have forfeited the right to assume the defense of such claim and will be bound by any determination made in such Proceeding or any compromise or settlement effected by the Purchaser Indemnified Party which may be effected without Seller’s consent.

(c) Notwithstanding the foregoing, if a Purchaser Indemnified Party determines in good faith that there is a reasonable probability that a Proceeding seeks material prospective relief which, if granted, may adversely affect it or its Affiliates other than as a result of monetary damages for which it would be entitled to indemnification under this Agreement, the Purchaser Indemnified Party may, by notice to Seller, assume the exclusive right to defend, compromise or settle such Proceeding, but Seller will not be bound by any compromise or settlement effected without its consent (which consent may not be unreasonably withheld, conditioned or delayed).

(d) The Parties hereby consent to the non-exclusive jurisdiction of any court in which a Proceeding is brought against any Purchaser Indemnified Party for purposes of any claim that a Purchaser Indemnified Party may have under this Agreement with respect to such Proceeding or the matters alleged therein, and agree that process may be served on such Persons with respect to such a claim anywhere in the world.

10.5. Procedure for Indemnification – Other Claims

A claim for indemnification for any matter not involving a third-party claim may be asserted by notice to Seller by a Purchaser Indemnified Party.

10.6. Holdback; Satisfaction of Losses.

Subject to Section 10.3:

(a) The Holdback Amount shall be used to satisfy any Damages of any Purchaser Indemnified Party for which an indemnification notice under this Section 10 shall have been delivered on or prior to the due date of the Final Earn-Out Payment. On the due date of Earn-Out Payment #3, the Purchaser shall pay to Seller an amount equal to (i) twenty-five percent (25%) of the Holdback Amount, minus (ii) any amounts previously paid or currently payable from the Holdback Amount to a Purchaser Indemnified Party for satisfaction of Final Determinations, and minus (iii) the Pending Claim Holdback Amount as of that date. If the result of the foregoing calculations is zero or a negative figure, Purchaser shall not pay any amount to Seller under this paragraph, and the portion of any Pending Claim Holdback Amount that is not offset against the Holdback release, together with any unsatisfied amount owing under a Final Determination, shall be rolled over for offset against subsequent Holdback releases.

Likewise, on each of the respective due dates of Earn-Out Payment #4 and Earn-Out Payment #5, the Purchaser shall pay to Seller an amount equal to (i) twenty-five percent (25%) of the Holdback Amount, minus (ii) any amounts previously paid or currently payable from the Holdback Amount to a Purchaser Indemnified Party for satisfaction of Final Determinations and not offset against previous Holdback releases, and minus (iii) the Pending Claim Holdback Amount as of that date. If the result of the foregoing calculations is zero or a negative figure, Purchaser shall not pay any amount to Seller under this paragraph, and the portion of any Pending Claim Holdback Amount that is not offset against the Holdback release, together with any unsatisfied amount owing under a Final Determination, shall be rolled over for offset against subsequent Holdback releases.

On the due date of the Final Earn-Out Payment, the Purchaser may offset against the remaining Holdback component of the Final Earn-Out payment an amount equal to (i) any amounts previously paid from the Holdback Amount to a Purchaser Indemnified Party for satisfaction of Final Determinations and not offset against previous Holdback releases, plus (ii) any amount currently payable as a result of a Final Determination, plus (iii) the Pending Claim Holdback Amount as of that date, but the offset described in this paragraph shall not exceed 25% of the Holdback Amount. Additional offsets on account of unsatisfied Final Determinations are provided for separately in paragraph (b) below.

The Pending Claim Holdback Amount shall be held as security and used by Purchaser to satisfy any such disputed claims on a dollar-for-dollar basis. If there is a Final Determination that no Purchaser Indemnified Party is entitled to any portion of the Pending Claim Holdback Amount or any portion of the Pending Claim Holdback Amount is not used to set-off against any such pending claims (the “Pending Claim Holdback Excess”), the Pending Claim Holdback Excess shall be payable at such time to Seller. If there is a Final Determination pursuant to this Section 10 that a Purchaser Indemnified Party is entitled to an amount exceeding the Pending Claim Holdback Amount, Seller shall pay such deficient amount to the Purchaser Indemnified Party subject to the limitations set forth in Section 10.3.

(b) Any indemnification obligations owed to a Purchaser Indemnified Party shall be satisfied first by set-off against the Holdback Amount or the Pending Claim Holdback Amount, as applicable, by reducing the Holdback Amount or the Pending Claim Holdback Amount, as applicable, on a dollar-for-dollar basis by the amount of such indemnification obligations, unless or until the Holdback Amount, or Pending Claim Holdback Amount, if applicable, has been reduced to zero. Once the Holdback Amount and the Pending Claim Escrow Amount has been reduced to zero, any remaining indemnification owing to a Purchaser Indemnified Party pursuant to this Section 10 shall be satisfied by set-off against any Earn-Out Payments not yet paid, and if such set-off is insufficient to discharge the remaining indemnification obligation, such obligation shall be effected by payment within fifteen (15) Business Days after the Final Determination thereof by wire transfer of immediately available funds from Seller to an account designated in writing by the Purchaser Indemnified Party.

10.7. Tax Treatment

Any payments made by Seller to satisfy indemnification obligations under this Section 10 shall be treated as an adjustment to the Purchase Price for Federal income tax purposes.

11. GENERAL PROVISIONS

11.1. Expenses

Except as otherwise expressly provided in this Agreement, each Party will bear its own expenses incurred in connection with the preparation, negotiation, execution and performance of this Agreement, the other Transaction Documents and the Contemplated Transactions, including all fees and expenses of agents, representatives, counsel and accountants (whether consummated or not). In the event of termination of this Agreement, the obligation of each Party to pay its own expenses will be subject to any rights of such Party arising from a breach of this Agreement by another Party.

11.2. Public Announcements

No Party shall issue any press release or make any public announcement relating to the subject matter of this Agreement or the Contemplated Transactions without the prior written approval of the other Party, except that either Seller, on the one hand, or the Purchaser, on the other hand, upon prior written notice to the other, may make any public disclosure it believes in good faith is required by applicable law, or any listing or trading agreement concerning the publicly-traded securities of any Affiliate of Purchaser or Seller.

11.3. Notices

All notices, consents, waivers and other communications under this Agreement must be in writing and will be deemed to have been duly given when (i) delivered by hand (with written confirmation of receipt), (ii) sent by telecopier (with machine generated confirmation of receipt), or (iii) when received by the addressee, if sent by a nationally recognized overnight delivery service (receipt requested), in each case to the appropriate addresses and telecopier numbers set forth below (or to such other addresses and telecopier numbers as a Party may designate by notice to the other Parties):

If to Seller:

Core Oncology, Inc.

7525 SE 24th Street

Suite 650

Mercer Island, WA 98040

Attention: Travis Gay

Chief Executive Officer

Telecopier: 206-926-2300

with a copy to:

DLA Piper

701 Fifth Avenue

Suite 7000

Seattle, WA 98104

Attention: Asher Bearman or Trenton Dykes

and to:

EverBank

501 Riverside Avenue

Suite 900

Jacksonville, FL 32202

Attention: Michael Brown or William Gulliford III

Telecopier: 904-623-7030

If to the Purchaser, to:

Theragenics Corporation

5203 Bristol Industrial Way

Buford, GA 30518

Attention: Francis J. Tarallo

Chief Financial Officer

Telecopier: (678) 482-4909

with a copy to:

Bryan Cave LLP

One Atlantic Center, Fourteenth Floor

1201 West Peachtree Street, N.E.

Atlanta, Georgia 30309-3488

Attention: Rick Miller

Telecopier: (404) 420-0787

11.4. Further Assurances

If, at any time after the Effective Time, Purchaser shall consider or be advised that any further deeds, assignments or assurances in law or any other acts are necessary or desirable to (i) vest, perfect or confirm, of record or otherwise, in Purchaser its right, title or interest in, to or under any of the Acquired Assets or Assumed Liabilities, or (ii) otherwise carry out the provisions of this Agreement, Seller, and its Representatives, shall be deemed to have granted to Purchaser an irrevocable power of attorney to execute and deliver all such deeds, assignments or assurances in law and to take all acts necessary, proper or desirable to vest, perfect or confirm title to and possession of such Acquired Assets and Assumed Liabilities in Purchaser and otherwise to carry out the provisions of this Agreement, and the Representatives of the Purchaser are authorized in the name of Seller or otherwise to take any and all such action.

11.5. Waiver

The rights and remedies of the Parties are cumulative and not alternative. Neither the failure nor any delay by any Party in exercising any right, power or privilege under the Transaction Documents will operate as a waiver of such right, power or privilege, and no single or partial exercise of any such right, power, or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by applicable Legal Requirement, (i) no claim or right arising out of the Transaction Documents can be discharged by one Party, in whole or in part, by a waiver or renunciation of the claim or right unless in writing signed by each other Party; (ii) no waiver that may be given by a Party will be applicable except in the specific instance for which it is given; and (iii) no notice to or demand on one Party will be deemed to be a waiver of any obligation of such Party or of the right of the Party giving such notice or demand to take further action without notice or demand as provided in the Transaction Documents.

11.6. Entire Agreement and Modification

This Agreement supersedes all prior agreements between the Parties with respect to its subject matter and constitutes (along with the Transaction Documents and other documents referred to in this Agreement) a complete and exclusive statement of the terms of the agreement between the Parties with respect to its subject matter, with the exception of that certain Confidentiality Agreement between Purchaser and Seller dated October 24, 2011, which shall remain in full force and effect in accordance with its terms until the Effective Time. This Agreement may not be amended except by a written agreement executed by each of the Parties.

11.7. Disclosure Schedules

(a) The disclosures in the Disclosure Schedules relate only to the representations and warranties in the Section of the Agreement to which they expressly relate and not to any other representation or warranty in this Agreement unless it is clear on its face that such disclosures relate to such other representation or warranty.

(b) In the event of any inconsistency between the statements in the body of this Agreement and those in the Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules with respect to a specifically identified representation or warranty), the statements in the body of this Agreement will control.

(c) No due diligence conducted by Purchaser shall limit or be used as a defense by Seller with respect to any claim of breach of a representation, warranty or covenant by Seller under any Transaction Document.

11.8. Assignments, Successors, and No Third-Party Rights

No Party may assign all or any portion of its rights under this Agreement without the prior written consent of the other Parties, except that Purchaser may assign any of its rights under this Agreement to any Affiliate of Purchaser without the consent of Seller. This Agreement will apply to, be binding in all respects upon, and inure to the benefit of the successors and permitted assigns of the Parties. Nothing expressed or referred to in this Agreement will be construed to give any Person other than the Parties any legal or equitable right, remedy or claim under or with respect to this Agreement or any provision of this Agreement. This Agreement and all of its provisions and conditions are for the sole and exclusive benefit of the Parties and their successors and permitted assigns.

11.9. Severability

If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. Upon a determination that any term or provision of this Agreement is illegal, invalid or incapable of being enforced, Purchaser and Seller shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner so that the Contemplated Transactions may be fulfilled to the greatest extent possible.

11.10. Time of Essence

With regard to all dates and time periods set forth or referred to in this Agreement, time is of the essence.

11.11. Governing Law; Consent to Jurisdiction; Waiver of Jury Trial

(a) This Agreement is made pursuant to, and shall be construed and enforced in accordance with, the laws of the State of Delaware applicable to contracts executed in and to be performed in that State, irrespective of the principal place of business, residence or domicile of the Parties, and without giving effect to otherwise applicable principles of conflicts of law. Any Proceeding arising out of or relating to this Agreement shall be instituted, heard and determined exclusively in any federal court or in any state court located in Delaware, and each Party hereby waives any objection that such Party may now or hereafter have to the laying of the venue of any such Proceeding, and hereby irrevocably and unconditionally submits to the jurisdiction of any such court. Any and all service of process and any other notice in any such Proceeding shall be effective against any Party if given as provided in Section 11.3. Nothing herein contained shall be deemed to affect the right of any Party to serve process in any other manner permitted by applicable Legal Requirement.

(b) Each Party hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, trial by jury in any suit, action or Proceeding arising under this Agreement or any other Transaction Document.

11.12. Specific Performance

Each of the Parties acknowledges and agrees that the other Party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached. Accordingly, each of the Parties agrees that the other Party shall be entitled to an injunction or injunctions to prevent breaches of the provisions of this Agreement or any of the other Transaction Documents and to enforce specifically this Agreement, any other Transaction Document, the terms and provisions hereof and of any other Transaction Document in any action instituted in any court of the United States or any state thereof having jurisdiction over the Parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity.

11.13. No Strict Construction

The language used in this Agreement will be deemed to be the language jointly chosen by the Parties hereto to express their mutual intent, and no rule of strict construction will be applied against any Person. No provision of this Agreement will be interpreted in favor of, or against, any of the Parties by reason of the extent to which either such Party or its counsel participated in the drafting thereof or by reason of the extent to which any such provision is inconsistent with any prior draft hereof or thereof.

11.14. Use of Name

Purchaser agrees that it will, as of the Closing Date and thereafter, refrain from adopting or using the words “Core Oncology” or any derivative thereof in association with any trade or business carried on by Purchaser after the Closing Date except as otherwise expressly permitted pursuant to this Section 11.14. Seller, to the extent it has rights thereto, grants Purchaser a non-exclusive license to use the words “Core Oncology” or any derivative thereof and associated logos, UPC codes, trademarks, etc., for the purpose of disposing of or realizing the use, benefit, or value of any Acquired Inventory, and “Products” (as that term is defined under the Temporary Manufacturing and Supply Agreement) that may have been labeled, packaged, or otherwise associated with such words. Such non-exclusive license shall be for a term beginning on the Closing Date and ending on the earlier of (i) the sale by Purchaser of goods using such labels and/or packaging materials, or (ii) the one (1) year anniversary of the Closing Date.

11.15. Appendices, Exhibits and Schedules

The Appendices, Exhibits and Schedules constitute a part of this Agreement and are incorporated into this Agreement for all purposes.

11.16. Counterparts

This Agreement may be executed in one or more counterparts (including by .pdf or facsimile), each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement.

11.17. Acquired Equipment/Additional Equipment

(a) Purchaser and its approved contractors (approval not to be unreasonably withheld by Seller), shall be granted reasonable access during normal business hours to Seller’s premises where any Acquired Equipment is located for the purpose of disassembling the Acquired Equipment and the removal thereof from such premises. Such work shall be done in a workmanlike manner and in compliance with all applicable Legal Requirements. The removal of any Acquired Equipment and completion of associated work shall be done at the cost and expense of Purchaser and any such costs and expenses shall be in addition to the Purchase Price. Seller shall assist and provide direction to Purchaser and Purchaser’s agents in preparing any Acquired Equipment for disassembly, removal, crating and shipping on common carriers. Seller shall provide a list of approved contractors and assist Purchaser in making arrangements with contractors selected by Purchaser to complete the work.

(b) Seller shall keep any Acquired Equipment insured until the Closing Date and until it is no longer used by Seller to perform its obligations under the Temporary Manufacturing and Supply Agreement.

(c) All damage, other than ordinary wear and tear, incurred to Seller’s premises resulting from the removal of any Acquired Equipment shall be repaired by and at the expense of Purchaser.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the Parties have executed and delivered this Asset Purchase Agreement as of the date first written above.

	PURCHASER:

	Theragenics Corporation

	By:	/s/ Frank Tarallo
	Name: Frank Tarallo
	Title: Chief Financial Officer

	SELLER:

	Core Oncology, Inc.

	By:	/s/ Travis Gay
	Name: Travis Gay
	Title: President and Chief Executive Officer

	SUBJECT SHAREHOLDER:

	/s/ Travis Gay
	Name: Travis Gay

Execution Page

Core Asset Purchase Agreement

Annex I

Definitions

“Accounting Firm” – means an independent accounting firm having no material relationship with Purchaser or Seller and mutually agreed upon by Purchaser and Seller.

“Acquired Assets” – means the following assets associated with the Business:

(a) all Contracts listed on Schedule 3.12(c) hereto (the “Acquired Contracts”);

(b) a list on Schedule 3.13(a) of all Core Customers and all other customers who have purchased products and services of the Business at any time during the 18 month period prior to and ending on the Closing Date, regardless of whether or not such purchases were pursuant to a contract, open purchase order or other arrangement (the “Customer List”);

(d) the equipment and machinery listed on Schedule 3.5 hereto, including the assets listed on Schedule 3.5 related to the packaging technologies, together with any express or implied warranty by the manufacturers or sellers of any item or component part thereof and all maintenance records and other documents relating thereto (the “Acquired Equipment”);

(e) the Acquired Intellectual Property, goodwill associated therewith, licenses and sublicenses granted and obtained with respect thereto, and rights thereunder, remedies against infringements thereof, and rights to protection of interests therein under the Legal Requirements of all jurisdictions;

(f) all refunds, rights of set off, and rights of recoupment with respect to the Acquired Assets and Assumed Liabilities;

(g) all Governmental Authorizations with respect to the Acquired Assets and Assumed Liabilities, to the extent transferable;

(h) all books, files, documents, studies, reports and other printed or written materials with respect to the Acquired Assets, the Assumed Liabilities and the Acquired Intellectual Property (the “Business Records”);

(i) insurance benefits, including rights and proceeds, arising from or relating to the Acquired Assets and the Assumed Liabilities prior to the Effective Time; and

(j) claims of Seller against third parties relating to the Acquired Assets, whether choate or inchoate, known or unknown, contingent or non-contingent;

(k) all marketing collateral, promotional items and similar items related to the Acquired Assets and the products of the Business;

Annex I-1

Core Asset Purchase Agreement

provided, however, that notwithstanding the foregoing, the Acquired Assets shall not include the following assets (the following referred to as the “Excluded Assets”) unless specifically included on a schedule to this Agreement:

(l) any owned or leased real property of Seller including, for the avoidance of doubt, Seller’s manufacturing facility located in Oklahoma City, Oklahoma;

(m) those assets of the Seller that do not relate to, or are not used in the conduct of, the Business;

(n) all Contracts other than the Acquired Contracts;

(o) all equipment and machinery other than the Acquired Equipment, including, for the avoidance of doubt, any prostate seed manufacturing equipment owned or leased by Seller;

(p) all inventory other than the Acquired Inventory;

(q) all intellectual property rights other than the Acquired Intellectual Property;

(r) all cash and cash equivalents held by Seller;

(s) all accounts receivable held by Seller;

(t) all bank accounts of Seller;

(u) any rights or interests in and with respect to any Company Plan;

(v) any rights or interests in any personal property leases, loans, advances, indentures, mortgages, lines of credit, instruments, Security Interests, guaranties or other similar arrangements constituting Indebtedness of Seller to third parties;

(w) the Organizational Documents, qualifications to conduct business as a foreign entity, arrangements with registered agents relating to foreign qualifications, taxpayer and other identification numbers, seals, minute books, stock transfer books, stock certificates, original Tax Returns and other documents relating to the organization, maintenance and existence of Seller; and

(x) any and all of the rights of Seller under this Agreement and the other Transaction Documents.

“Acquired Contracts” – see definition of Acquired Assets.

“Acquired Equipment” – see definition of Acquired Assets.

Annex I-2

Core Asset Purchase Agreement

“Acquired Intellectual Property” – means rights, as described below, in (i) all Intellectual Property that is used by Seller in the Business as of the Closing Date or has been used in the Business since January 1, 2009, including, without limitation, all the Trademarks listed in Schedule 3.16 (being referred to herein as the “Business Trademarks”) and all Intellectual Property rights associated therewith; (ii) the Domain Names set forth on Schedule 3.16; (iii) all Intellectual Property rights of Seller in and to the Acquired Equipment, the design thereof or the method of use thereof, subject to the conditions in this definition below; and (iv) any and all Intellectual Property rights of Seller in and to the formulation or composition of, or methods of manufacture of, the brachytherapy products marketed under any of the Business Trademarks. The Acquired Intellectual Property consists of four categories: Closing Purchased Intellectual Property, Nonexclusive Intellectual Property, Deferred Purchased Intellectual Property, and the ProstaSeed Mark, as follows:

“Closing Purchased Intellectual Property” consists of all Acquired Intellectual Property that is operative or enforceable within North America (United States, Canada and Mexico) and relates to Seller’s C-20 cartridge line (including the C-20 flat pack) and all Acquired Intellectual Property that relates to Seller’s Isoloader product line, including the Isoloader console and software and all Isoloader-related modules, accessories and similar products such as the IsoStrand strand loading module and the IsoCheck and IsoCartridge products; Seller will transfer clear title to the Closing Purchased Intellectual Property to Purchaser at Closing.

“Nonexclusive Intellectual Property” consists of all Acquired Intellectual Property, such as the rights in any methods of manufacture, formulations, or compositions of any products marketed under the Business Trademarks, or in the designs or methods of use of any of the Acquired Equipment, where such methods, formulations, compositions, or designs are not used exclusively in the Business but are also used in the manufacture of other existing products of Seller or any of its Affiliates; Seller shall grant to Purchaser at Closing a worldwide, royalty-free, perpetual, irrevocable, unrestricted, transferable and sublicenseable license (the “Nonexclusive IP License”) to such Nonexclusive Intellectual Property, which shall be evidenced by a license agreement in a form satisfactory to Purchaser to be delivered on the Closing Date, reasonably describing the Nonexclusive Intellectual Property and granting the above license rights therein to Purchaser.

“Deferred Purchased Intellectual Property” consists of all of the Acquired Intellectual Property that is not either Closing Purchased Intellectual Property, nor Nonexclusive Intellectual Property, nor the ProstaSeed Mark. Without limiting the generality of the foregoing, the Deferred Purchased Intellectual Property specifically includes, among other things, the worldwide rights outside North America to the entire C-20 cartridge product line and the entire Isoloader product line described above. Seller’s transfer of clear title to the Deferred Purchased Intellectual Property to Purchaser pursuant to the Bill of Sale shall expressly be effective only upon receipt of the Final Earn-Out Payment. At Closing, Seller will grant to Purchaser a worldwide, exclusive, royalty-free, perpetual, irrevocable, unrestricted, transferable and sublicenseable license (the “Deferred Purchased IP License”) to such Deferred Purchased Intellectual Property, which shall be evidenced by a license agreement in a form satisfactory to Purchaser to be delivered on the Closing Date, reasonably describing the Deferred Purchased Intellectual Property and granting the above license rights therein to Purchaser. The license may provide that upon a default by Purchaser in making any of the Earn-Out payments hereunder, which is not cured within thirty (30) days after written notice to Purchaser reasonably describing the default, Seller shall be entitled to declare the Deferred Purchased Intellectual Property License nonexclusive and to pursue the grant of other nonexclusive licenses to the Deferred Purchased Intellectual Property to third parties; provided that once Purchaser cures its default, Purchaser’s license shall once again become exclusive, subject only to the continued existence of any nonexclusive rights granted by Seller during the nonexclusive period.

Annex I-3

Core Asset Purchase Agreement

The “ProstaSeed Marks” consists of the Trademark “ProstaSeed” (including all typographical or graphic renditions thereof) and all registrations thereof and applications for registration throughout the world, for brachytherapy seeds. The ProstaSeed Marks shall be licensed to Purchaser under the Deferred Purchased IP License, with special provisions relating to the ProstaSeed Marks as follows: (a) the license to the ProstaSeed Marks will expire upon receipt of the Final Earn-Out Payment, or upon the expiration of the Temporary Manufacturing and Supply Agreement, whichever occurs later; and (b) upon expiration of the license to the ProstaSeed Marks, the ProstaSeed Marks will not be transferred to Purchaser but will remain the property of Seller.

“Acquired Inventory” – see definition of Acquired Assets.

“Acquisition Proposal” – as defined in Section 5.6.

“Affiliate” – used to indicate a relationship to a specified Person, firm, corporation, partnership, limited liability company, association or entity, and means any Person, firm, corporation, partnership, limited liability company, association or entity that, directly or indirectly or through one or more intermediaries, controls, is controlled by or is under common control with such Person, firm, corporation, partnership, limited liability company, association or entity.

“Agreement” – as defined in the first paragraph of this Agreement.

“Assignment and Assumption Agreement” – as defined in Section 2.1(b).

“Assumed Liabilities” – means Seller’s performance obligations that arise and become due and owing following the Effective Time under the Acquired Contracts; provided, however, that notwithstanding the foregoing, the Assumed Liabilities shall not include (the following referred to herein as the “Excluded Liabilities”):

(a) any Liability of Seller with respect to any of the Excluded Assets;

(b) any Liability of Seller for any Indebtedness of any nature whatsoever, whether or not reflected on the financial statements of Seller;

(c) any Liability of Seller relating to any claim that the operation of the Business (or Seller’s other businesses) on or prior to the Closing Date or the consummation of the Contemplated Transactions violated any Legal Requirement or the rights of any third parties (under Contract, in tort or otherwise);

Annex I-4

Core Asset Purchase Agreement

(d) any Liability arising out of or relating to products sold by Seller to the extent manufactured or sold prior to the Effective Time;

(e) any Liability of Seller relating to employees of Seller, including but not limited to employee compensation, bonuses, commissions, incentive compensation, sick pay, vacation pay, severance pay, workers’ compensation and payroll and other employer-related withholding obligations and any entitlements due to any employees, whether by contractual obligation or normal business expectation, or pursuant to any stock appreciation or phantom stock plan or program;

(f) Liabilities under the Acquired Contracts outstanding, or that relate to events or occurrences, prior to the Effective Time;

(g) any Environmental Health and Safety Liabilities of Seller;

(h) any Liability arising out of or relating to any grievance of any employee of Seller, whether or not the affected employees are hired by Purchaser;

(i) any Liability arising out of any Proceeding pending as of the Effective Time;

(j) any Liability arising out of any Proceeding commenced after the Effective Time and arising out of or relating to any occurrence or event happening prior to the Effective Time;

(k) any Liability for Taxes, including (i) any Taxes arising as a result of Seller’s operation of the Business or ownership of the Acquired Assets prior to the Effective Time, (ii) any Taxes that will arise as a result of the sale of the Acquired Assets pursuant to this Agreement and (iii) any deferred Taxes of Seller of any nature;

(l) any Liability arising under the violation of any Legal Requirement by Seller; or

(m) other than the Assumed Liabilities, any other Liability of Seller, whether absolute, contingent or otherwise, known or unknown, accrued or unaccrued, asserted or unasserted, or otherwise.

“Base Amount” – means Four Million and No/100 Dollars ($4,000,000) (See Section 2.2(a)).

“Best Efforts” – means the efforts that a prudent Person desirous of achieving a result would use in similar circumstances to ensure that such result is achieved as expeditiously as possible; provided, however, that for purposes of this Agreement, “Best Efforts” will not be deemed to require a Person to undertake any extraordinary or unreasonable measures, including, without limitation, any payments with respect to any Acquired Contract that are material in the context of such Acquired Contract (or material on an aggregate basis as to all Acquired Contracts).

Annex I-5

Core Asset Purchase Agreement

“Bill of Sale” – as defined in Section 2.1(a).

“Breast Brachytherapy Business” – as defined in the Recitals.

“Business Day” – means any day except Saturday, Sunday or any day on which banks are generally not open for business in Atlanta, Georgia.

“Business” – as defined in the Recitals.

“Closing” – as defined in Section 2.4.

“Closing Cash Payment” – as defined in Section 2.2(a).

“Closing Date” – as defined in Section 2.4.

“Closing Purchased Intellectual Property” – See definition of Acquired Intellectual Property.

“COBRA” – means IRC Section 4980B and Part 6, Subtitle B of Title I of ERISA.

“Company Plans” – means all of the Employee Benefit Plans that are presently in effect or that have previously been in effect since December 31, 2008, for the benefit of current or former employees, officers, partners or consultants of the Business.

“Competing Business” – means any Person that is engaged in the business of manufacturing, distributing, marketing and selling brachytherapy seeds and related products for the treatment of prostate cancer. For avoidance of doubt, the Breast Brachytherapy Business is not a Competing Business.

“Confidential Information” – means information with respect to the terms of the transactions contemplated by this Agreement and the other Transaction Documents, and trade secrets, discoveries, ideas, concepts, know-how, techniques, designs, specifications, data, computer programs pricing and customer information, interpretations, financial statements, forecasts, reports, records, plans, studies and other technical and business information of the disclosing party, whether in oral, written, graphic, electronic or other form as well as analyses, compilations, studies or other documents, whether or not prepared by the receiving party or its Representatives, which contain or otherwise reflect such information. Notwithstanding the foregoing, the following information shall not be Confidential Information: (i) information which has become generally available to the general public other than as a result of a disclosure by the receiving party or its Representatives, or (ii) information which becomes available to the receiving party on a non-confidential basis from a third party who was itself not prohibited from transmitting the information to the receiving party by a contractual, legal or fiduciary obligation.

“Consent” – means any approval, consent, ratification, waiver or other authorization (including any Governmental Authorization).

Annex I-6

Core Asset Purchase Agreement

“Contemplated Transactions” – means all of the transactions contemplated by this Agreement and the other Transaction Documents including but not limited to (i) the acquisition of the Acquired Assets and the assumption of the Assumed Liabilities by Purchaser from Seller, Purchaser’s exercise of control over the Business following the Closing, and the payment of the Purchase Price therefor; and (ii) the execution, delivery and performance of this Agreement and the other Transaction Documents.

“Contract” – means any agreement, contract, obligation, promise or undertaking (whether written or oral and whether express or implied) that is legally binding.

“Core Customers” – means those prostate brachytherapy customers listed on Schedule 3.13 who, for the 18 month period prior to and ending on the Closing Date, have been and continue to be actively and regularly purchasing brachytherapy seeds used in the treatment of prostate cancer (both Pd-103 or I-125 seeds or both) from Seller pursuant to an existing contract, open purchase order or other established and ongoing course of dealing.

“Customer List” – see definition of Acquired Assets.

“Damages” – as defined in Section 10.2.

“Deferred Purchased Intellectual Property” – See definition of Acquired Intellectual Property.

“Deferred Purchased IP License” – See definition of Acquired Intellectual Property.

“Disclosure Schedules” – as defined in Section 2.6.

“Domain Names” – see definition of Intellectual Property.

“Earn-Out Payment” – means any one of Earn-Out Payment #1, Earn-Out Payment #2, Earn-Out Payment #3, Earn-Out Payment #4, Earn-Out Payment #5, and the Final Earn-Out Payment. “Earn-Out Payments” refers generically to any two or more of such payments, as the context requires.

“Earn-Out Payment #1” - means an amount equal to the result obtained by multiplying 66.66% of the Revenue Multiple by the Net Revenue recognized by Purchaser from the Core Customers over the three month period beginning on the first day of the month immediately following the month in which the Closing Date occurs and ending on the last day of the third month immediately following the month in which the Closing Date occurs, with the result reduced by (i) 10.00% of the Base Amount and (ii) 10.00% of the Threshold Amount.

“Earn-Out Payment #2” - means an amount equal to the result obtained by multiplying 66.66% of the Revenue Multiple by the Net Revenue recognized by Purchaser from the Core Customers over the three month period beginning on the first day of the fourth month immediately following the month in which the Closing Date occurs and ending on the last day of the sixth month immediately following the month in which the Closing Date occurs, with the result reduced by (i) 10.00% of the Base Amount, (ii) 10.00% of the Threshold Amount, and (iii) any unused carryforward of negative amounts from the calculation of Earn-Out Payment #1 as described in the final paragraph of Section 2.2.

Annex I-7

Core Asset Purchase Agreement

“Earn-Out Payment #3” - means an amount equal to the result obtained by multiplying 66.66% of the Revenue Multiple by the Net Revenue recognized by Purchaser from the Core Customers over the three month period beginning on the first day of the seventh month immediately following the month in which the Closing Date occurs and ending on the last day of the ninth month immediately following the month in which the Closing Date occurs, with the result reduced by (i) 20.00% of the Base Amount, (ii) 20.00% of the Threshold Amount, and (iii) any unused carryforward of negative amounts from the calculation of previous Earn-Out Payments as described in the final paragraph of Section 2.2.

“Earn-Out Payment #4” - means an amount equal to the result obtained by multiplying 66.66% of the Revenue Multiple by the Net Revenue recognized by Purchaser from the Core Customers over the three month period beginning on the first day of the tenth month immediately following the month in which the Closing Date occurs and ending on the last day of the twelfth month immediately following the month in which the Closing Date occurs, with the result reduced by (i) 20.00% of the Base Amount, (ii) 20.00% of the Threshold Amount, and (iii) any unused carryforward of negative amounts from the calculation of previous Earn-Out Payments as described in the final paragraph of Section 2.2.

“Earn-Out Payment #5” - means an amount equal to the result obtained by multiplying 66.66% of the Revenue Multiple by the Net Revenue recognized by Purchaser from the Core Customers over the three month period beginning on the first day of the thirteenth month immediately following the month in which the Closing Date occurs and ending on the last day of the fifteenth month immediately following the month in which the Closing Date occurs, with the result reduced by (i) 20.00% of the Base Amount, (ii) 20.00% of the Threshold Amount, and (iii) any unused carryforward of negative amounts from the calculation of previous Earn-Out Payments as described in the final paragraph of Section 2.2.

“Effective Time” – means 11:59 p.m. Eastern Time on the Closing Date.

“Employee Benefit Plans” – means any (i) nonqualified deferred compensation or retirement plan or arrangement, including any “employee pension benefit plan” (as defined in ERISA Section 3(2)), (ii) qualified defined contribution retirement plan or arrangement, including any “employee pension benefit plan”, (iii) qualified defined benefit retirement plan or arrangement, including any “employee pension benefit plan” (including any “multiemployer plan” (as defined in ERISA Section 3(37))), (iv) employee welfare benefit plan, including any “employee welfare benefit plan” (as defined in ERISA Section 3(1)), (v) fringe benefit plan or program, and (vi) each employment, severance, salary continuation or other contract, incentive plan, insurance plan arrangement, bonus plan and any equity plan or arrangement without regard to whether such plan, arrangement, program or contract exists under United States or any similar non-United States Legal Requirement.

“Environment” – means soil, land surface or subsurface strata, surface waters (including navigable waters, ocean waters, streams, ponds, natural or artificial drainage systems, and wetlands), ground waters, drinking water supply, stream sediments, ambient air (including indoor air), plant and animal life, biota, and any other environmental medium or natural resource.

Annex I-8

Core Asset Purchase Agreement

“Environmental, Health, and Safety Liabilities” – means any cost, damages, expense (including, but not limited to, engineering, consulting and laboratory fees and expenses), liability, obligation, or other responsibility arising from or under Environmental Law or Occupational Safety and Health Law, including, but not limited to, fines, penalties, financial responsibility for cleanup costs, corrective action, removal, remedial actions and response actions, and any other compliance, corrective, investigative, or remedial measures required under Environmental Law or Occupational Safety and Health Law or by Governmental Bodies or third-party claims or actions. The terms “removal,” “remedial,” and “response action,” include the types of activities covered by the United States Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. § 9601 et seq., as amended (“CERCLA”).

“Environmental Law” – means any federal, state or local Legal Requirement (including but not limited to nuisance or trespass claims), and any judicial interpretation of any of the foregoing, which pertains to health, safety, any Hazardous Material, or the Environment (including but not limited to ground, air, water or noise pollution or contamination, and underground or above-ground storage tanks) and shall include the Solid Waste Disposal Act, 42 U.S.C. § 1801 et seq.; CERCLA, as amended by the Superfund Amendments and Reauthorization Act of 1986; the Hazardous Materials Transportation Act, 49 U.S.C. § 1801 et. seq.; the Federal Water Pollution Control Act, 33 U.S.C. § 1251 et seq.; the Clean Air Act, 42 U.S.C. § 7401 et seq.; the Toxic Substances Control Act, 15 U.S.C. § 2601 et seq.; the Safe Drinking Water Act, 42 U.S.C. § 300f et seq. and any other local, state, or federal, or international environmental statutes, and all rules and regulations, orders and decrees now or hereafter promulgated under any of the foregoing, as any of the foregoing now exist or may be changed or amended or come into effect in the future.

“Environmental Permits” – as defined in Section 3.14(a).

“ERISA” – Employee Retirement Income Security Act of 1974, as amended.

“Excluded Assets” – see definition of Acquired Assets.

“Excluded Liabilities” – see definition of Assumed Liabilities.

“Family” – see definition of Related Person.

“Final Earn-Out Payment” – means an amount equal to the result obtained by multiplying the Revenue Multiple by the Net Revenue recognized by Purchaser from the Core Customers over the twelve month period beginning on the first day of the seventh month immediately following the month in which the Closing Date occurs and ending on the last day of the eighteenth month immediately following the month in which the Closing Date occurs, with the result reduced by (i) the Base Amount, (ii) the Threshold Amount, and (iii) each of the Earn-Out Payments #s 1 through 5.

“Final Determination” – means either (i) a binding, nonappealable decision of an arbitration panel or appellate court has been entered determining liability, or determining no liability, or (ii) Purchaser and Seller mutually agree in writing as to the amount of any liability.

“Financial Statements” – as defined in Section 3.7.

Annex I-9

Core Asset Purchase Agreement

“Fundamental Representations” – means those representations and warranties of Seller contained in Section 3.1 [Organization and Good Standing], Section 3.2 [Authority; No Conflict], Section 3.4 [Title to Properties; Security Interests], the first three sentences of Section 3.6 [Taxes]; Section 3.7 [Financial Statements], Section 3.14 [Environmental Matters] and Section 3.19 [Brokers and Finders].

“GAAP” – means United States generally accepted accounting principles, consistently applied, as in effect on the date hereof.

“Governmental Authorization” – means any approval, consent, license, permit, waiver or other authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Legal Requirement.

“Governmental Body” – means any federal, state, local, municipal, foreign or other government or governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official or entity and any court or other tribunal).

“Hazardous Materials” – means any substance, whether solid, liquid or gaseous: (i) which is listed, defined or regulated as a “hazardous substance,” “hazardous waste,” “contaminant,” or “solid waste,” or otherwise classified as hazardous or toxic, in or pursuant to any Environmental Law; or (ii) which is or contains asbestos, radon, any polychlorinated biphenyl, polybrominated diphenyl ether, urea formaldehyde foam insulation, explosive or radioactive material, or motor fuel, petroleum product, constituent or by-product, or other petroleum hydrocarbons; or (iii) which causes contamination or nuisance or hazard, or threat of the same, to public health, human health, or the Environment.

“Historical Financial Statements” – as defined in Section 3.7.

“Holdback Amount” – means Four Hundred Thousand and No/100 Dollars ($400,000).

“Indebtedness” – means (i) all indebtedness for borrowed money or for the deferred purchase price of property or services (including reimbursement and all other obligations with respect to surety bonds, letters of credit and bankers’ acceptances, whether or not matured), including the current portion of such indebtedness, (ii) all obligations evidenced by notes, bonds, debentures or similar instruments and (iii) all capital lease obligations.

“Intellectual Property” – means any or all of the following, and all rights in, arising out of, or associated therewith: (i) all United States, international and foreign patents and applications therefor and all reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part thereof; (ii) all inventions (whether or not patentable or patented), invention disclosures, improvements, trade secrets, proprietary information, know-how, technology, technical data and customer lists; (iii) all copyrights (whether registered or not), copyrights registrations and applications therefor and all other rights corresponding thereto throughout the world; (iv) all industrial designs and any registrations and applications therefor throughout the world; (v) all trade names, logos, trademarks and service marks, whether common law or registered, and all trademark and service mark registrations and applications therefor and all goodwill associated therewith throughout the world (“Trademarks”); (vi) all domain names, uniform resource locators and other Internet or similar addresses or identifiers (“Domain Names”); (vii) all databases and data collections and all rights therein throughout the world; and (viii) all computer software including all source code, object code, firmware, development tools, files, records and data, all media on which any of the foregoing is recorded; (ix) all moral and economic rights of authors and inventors, however denominated, throughout the world; (x) all rights to sue for past, present or future infringement or misappropriation of any of the foregoing; (xi) any similar, corresponding or equivalent rights to any of the foregoing and (xii) all documentation related to any of the foregoing.

Annex I-10

Core Asset Purchase Agreement

“Interim Financial Statements” – as defined in Section 3.7.

“IRC” – means the Internal Revenue Code of 1986, as amended, or any successor law, and regulations issued by the IRS pursuant to the Internal Revenue Code of 1986, as amended, or any successor law.

“IRS” – means the United States Internal Revenue Service and, to the extent relevant, the United States Department of the Treasury and, to the extent relevant, the counterpart agencies of other countries.

“Knowledge” – a Person will be deemed to have “Knowledge” of a particular fact or other matter if:

(a) such Person is actually aware of such fact or other matter; or

(b) a prudent individual could be expected to discover or otherwise become aware of such fact or other matter in the course of conducting a reasonable investigation concerning the existence of such fact or other matter.

“Knowledge” with respect to Seller shall mean the Knowledge of Travis Gay and Chris Nicholson.

“Knowledge” with respect to Purchaser shall mean the Knowledge of Frank Tarallo or Bruce Smith.

“Legal Requirement” – means any federal, state, local, municipal, foreign, international, multinational or other administrative order, constitution, law, ordinance, principle of common law, regulation, statute or treaty.

“Liability” – means any liability (whether known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, or due or to become due), including any liability for Taxes.

“Temporary Manufacturing and Supply Agreement” – as defined in the Recitals.

“Material Adverse Effect” – means, any effect or change that would be (or could reasonably be expected to be) materially adverse to the business, assets, condition (financial or otherwise), operating results, operations or prospects of the Business, taken as a whole, or to the ability of Seller to consummate timely the Contemplated Transactions (regardless of whether or not such adverse effect or change can be or has been cured at any time or whether Purchaser has Knowledge of such effect or change on the date hereof), excluding, however, any events or circumstances affecting the prostate brachytherapy industry generally unless such events or circumstances have (or are reasonably expected to have) a disproportionate affect on the Business.

Annex I-11

Core Asset Purchase Agreement

“Material Interest” – see definition of Related Person.

“Net Revenue” – means the revenue recognized from sales by Purchaser to the Core Customers after discounts, rebates and refunds over the period specified computed in accordance with GAAP, reduced by uncollectible amounts; provided, that Net Revenue does not include any revenue recognized from sales by Purchaser to the Shared Customers of products that Purchaser has historically sold to the Shared Customers either directly or through a distributor or reseller other than Seller.

“Net Revenue Period” – means the period over which Net Revenue is measured for purposes of a particular Earn-Out Payment, as described in the definition of the relevant Earn-Out Payment. For example, the Net Revenue Period applicable to Earn-Out Payment #1 is the three month period beginning on the first day of the month immediately following the month in which the Closing Date occurs and ending on the last day of the third month immediately following the month in which the Closing Date occurs; the Net Revenue Period applicable to Earn-Out Payment #2 is the three month period beginning on the first day of the fourth month immediately following the month in which the Closing Date occurs and ending on the last day of the sixth month immediately following the month in which the Closing Date occurs; and the Net Revenue Period applicable to the Final Earn-Out Payment is the twelve month period beginning on the first day of the seventh month immediately following the month in which the Closing Date occurs and ending on the last day of the eighteenth month immediately following the month in which the Closing Date occurs.

“Nonexclusive Intellectual Property” – see the definition of Acquired Intellectual Property.

“Nonexclusive IP License” – see the definition of Acquired Intellectual Property.

“Occupational Safety and Health Law” – means any Legal Requirement designed to provide safe and healthful working conditions and to reduce occupational safety and health hazards, and any program, whether governmental or private (including those promulgated or sponsored by industry associations and insurance companies), designed to provide safe and healthful working conditions.

“Operational Representations” – means those representations and warranties of Seller contained in Article 3 of this Agreement that are not Fundamental Representations.

“Order” – means any award, decision, injunction, judgment, order, ruling, subpoena or verdict entered, issued, made or rendered by any court, administrative agency or other Governmental Body or by any arbitrator.

Annex I-12

Core Asset Purchase Agreement

“Ordinary Course of Business” – an action taken by Seller will be deemed to have been taken in the “Ordinary Course of Business” only if such action is consistent with the past practices of Seller and is taken in the course of the normal day-to-day operations of Seller with respect to the Business and does not require the consent or approval of Seller’s Board of Directors or shareholders.

“Organizational Documents” – means (a) the articles or certificate of incorporation and the bylaws of a corporation; (b) the partnership agreement and any statement of partnership of a general partnership; (c) the limited partnership agreement and the certificate of limited partnership of a limited partnership; (d) the articles or certificate of formation and operating agreement of a limited liability company; (e) any trust agreement adopted in connection with any trust; and (f) any amendment to any of the foregoing.

“Party” and “Parties” – as defined in the first paragraph of this Agreement.

“Pending Claim Holdback Amount” – At any given time, an amount equal to Purchaser’s good faith estimate of the cumulative amount of all Damages then in dispute in any indemnification claims for Damages of any Purchaser Indemnified Party (including any previously-existing Pending Claim Holdback Amount that has not already been offset against a prior Holdback release). Damages claims that have become the subject of a Final Determination are not included in the Pending Claim Holdback Amount.

“Person” – means any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union or other entity or Governmental Body.

“Proceeding” – means any action, arbitration, audit, hearing, charge, investigation, litigation or suit (whether civil, criminal, administrative, investigative, or informal) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Body or arbitrator.

“Purchase Price” – as defined in Section 2.2.

“Purchase Price Allocation Methodology” – as defined in Section 2.6.

“Purchase Price Allocation Schedule” – as defined in Section 2.6.

“Purchaser” – as defined in the first paragraph of this Agreement.

“Purchaser Indemnified Parties” – as defined in Section 10.2.

“Registered Intellectual Property” – as defined in Section 3.16(a).

“Related Person” – means, with respect to a particular individual: (i) each other member of such individual’s Family; (ii) any Person that is directly or indirectly controlled by such individual or one or more members of such individual’s Family; (iii) any Person in which such individual or members of such individual’s Family hold (individually or in the aggregate) a Material Interest; and (iv) any Person with respect to which such individual or one or more members of such individual’s Family serves as a director, manager, officer, partner, executor, or trustee (or in a similar capacity). With respect to a specified Person other than an individual “Related Person” means: (A) any Person that directly or indirectly controls, is directly or indirectly controlled by, or is directly or indirectly under common control with such specified Person; (B) any Person that holds a Material Interest in such specified Person; (C) each Person that serves as a director, manager, officer, partner, executor, or trustee of such specified Person (or in a similar capacity); (D) any Person in which such specified Person holds a Material Interest; (E) any Person with respect to which such specified Person serves as a general partner or a trustee (or in a similar capacity); and (F) any Related Person of any individual described in clause (B) or (C).

Annex I-13

Core Asset Purchase Agreement

For purposes of this definition, (a) the “Family” of an individual includes (i) the individual, (ii) the individual’s spouse, (iii) any other natural person who is related to the individual or the individual’s spouse within the second degree, and (iv) any other natural person who resides with such individual, and (b) “Material Interest” means direct or indirect beneficial ownership (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of voting securities or other voting interests representing at least 10% of the outstanding voting power of a Person or equity securities or other equity interests representing at least 10% of the outstanding equity securities or equity interests in a Person.

“Release” or “Released” – means any spilling, leaking, pumping, pouring, emptying, injection, emitting, discharging, depositing, escaping, leaching, migration, filtration, pouring, seepage, disposal, dumping, or other releasing into the indoor or outdoor Environment, whether intentional or unintentional, including the movement of Hazardous Materials on or through the Environment.

“Representative” – means, with respect to a particular Person, any director, manager, officer, employee, agent, consultant, advisor or other representative of such Person, including legal counsel, accountants and financial advisors.

“Required Approvals” – as defined in Section 5.4.

“Revenue Multiple” – means a multiplier equal to 1.0.

“Security Interest” – means any charge, claim, community property interest, condition, equitable interest, encumbrance, mortgage, lien, option, pledge, security interest, right of first refusal or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.

“Seller” – as defined in the first paragraph of this Agreement.

“Shared Customers” – as defined in Section 3.13(a) and listed in Schedule 3.13(a)(ii).

“Tax” – means all taxes (including but not limited to income tax, payroll tax, capital gains tax, value added tax, sales or use tax, property tax, gift tax or estate tax), levy, assessment, tariff, duty (including but not limited to customs duty), deficiency or other fee and any related charge or amount (including but not limited to fine, penalty and interest) imposed, assessed or collected by or under the authority of any Governmental Body.

Annex I-14

Core Asset Purchase Agreement

“Tax Return” – means any return (including but not limited to any information return), report, statement, schedule, notice, form, or other document or information filed with or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Legal Requirement relating to any Tax.

“Territory” – means the Unites States, Canada, and South Africa.

“Threshold Amount” – means Two Million Five Hundred Thousand ($2,500,000.00) Dollars.

“Trademarks” – see definition of Intellectual Property.

“Transaction Documents” – means each of this Agreement, the Temporary Manufacturing and Supply Agreement, the Bill of Sale, the Assignment and Assumption Agreement and each other document, instrument and certificate delivered in connection herewith or therewith.

“Unregistered Marks” – as defined in Section 3.16(a).

Annex I-15

Core Asset Purchase Agreement

Asset Purchase Agreement by and between Theragenics Corporation and Core Oncology, Inc.

Annex -II

Example of Mechanics of Payments Under the

Agreement

This Annex-II is an example only and is intended to demonstrate the mathematical mechanics of the various payments that may become due under the Agreement. This Annex-II in no way provides for the actual amount of any of the payments which may become due, nor does it determine the amount of revenue from which any payment due may be calculated. Such actual payments are to be computed based on the actual revenues and terms and conditions as provided for in the Agreement.

Assumptions for purposes of this Annex-II
Base Amount	$	4,000,000
Threshold amount	$	2,500,000
Revenue multiple		1

Revenue amounts used for this example:
mos 1-3	$	2,500,000
mos 4-6	$	3,000,000
mos 7-9	$	3,250,000
mos 10-12	$	3,250,000
mos 13-15	$	3,250,000
mos 7-18	$	13,000,000

Core Asset Purchase Agreement

Earn-Out Payments are based upon:
mos 1-3	66.66	%
mos 4-6	66.66	%
mos 7-9	66.66	%
mos 10-12	66.66	%
mos 13-15	66.66	%
mos 7-18	100.00	%

	Earn-Out			Earn-Out			Earn-Out			Earn-Out			Earn-Out
	Payment #1			Payment #2			Payment #3			Payment #4			Payment #5
Adjustments are based upon:
Base amount		10.00	%		10.00	%		20.00	%		20.00	%		20.00	%
Threshold amount		10.00	%		10.00	%		20.00	%		20.00	%		20.00	%

Total pymts will be 1X revenue for mos 7 to 18, less Threshold amount	$	10,500,000

Core Asset Purchase Agreement

Example

	Upfront
	payment due			Earn-Out			Earn-Out			Earn-Out			Earn-Out			Earn-Out			Final Earn-Out
	at closing			Payment #1			Payment #2			Payment #3			Payment #4			Payment #5			Payment			Total

Upfront pymt	$	4,000,000
Pymt based on revenue multiple				$	1,666,500		$	1,999,800		$	2,166,450		$	2,166,450		$	2,166,450		$	13,000,000

Adjustments:
Base amount				$	(400,000	)	$	(400,000	)	$	(800,000	)	$	(800,000	)	$	(800,000	)	$	(4,000,000	)
Threshold amount				$	(250,000	)	$	(250,000	)	$	(500,000	)	$	(500,000	)	$	(500,000	)	$	(2,500,000	)
Earn-Out Payment #1																			$	(1,016,500	)
Earn-Out Payment #2																			$	(1,349,800	)
Earn-Out Payment #3																			$	(866,450	)
Earn-Out Payment #4																			$	(866,450	)
Earn-Out Payment #5																			$	(866,450	)


Subtotal	$	4,000,000		$	1,016,500		$	1,349,800		$	866,450		$	866,450		$	866,450		$	1,534,350		$	10,500,000
Hold back (assumes no claims for indemnity)	$	(200,000	)	$	(100,000	)	$	(100,000	)	$	100,000		$	100,000		$	100,000		$	100,000		$	-

Amount due	$	3,800,000		$	916,500		$	1,249,800		$	966,450		$	966,450		$	966,450		$	1,634,350		$	10,500,000

Core Asset Purchase Agreement

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (USD $)
In Thousands, except Per Share data, unless otherwise specified

3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

REVENUE

Product sales

$ 20,979

$ 19,738

License and fee income

604

515

Revenues, Total

21,583

20,253

COST OF SALES

12,974

12,286

GROSS PROFIT

8,609

7,967

OPERATING EXPENSES

Selling, general and administrative

5,901

5,847

Amortization of purchased intangibles

855

698

Research and development

277

535

Loss on disposal of assets

Operating Expenses, Total

7,033

7,081

EARNINGS FROM OPERATIONS

1,576

886

OTHER INCOME (EXPENSE)

Interest income

Interest expense

(164)

(177)

Other

Nonoperating Income (Expense), Total

(125)

(136)

EARNINGS BEFORE INCOME TAXES

1,451

750

Income tax expense

517

292

NET EARNINGS

934

458

EARNINGS PER SHARE:

Basic

$ 0.03

$ 0.01

Diluted

$ 0.03

$ 0.01

WEIGHTED AVERAGE SHARES

Basic

33,533

33,338

Diluted

33,941

33,645

COMPREHENSIVE EARNINGS

Net earnings

934

458

Other comprehensive earnings, net of taxes

Reclassification adjustment for (gain) loss included in net earnings

(1)

Unrealized gains on securities arising during the period

Total other comprehensive earnings

Total comprehensive earnings

$ 990

$ 464

BASIS OF PRESENTATION AND DESCRIPTION OF BUSINESS

3 Months Ended

Mar. 31, 2012

BASIS OF PRESENTATION AND DESCRIPTION OF BUSINESS

NOTE A - BASIS OF PRESENTATION AND DESCRIPTION OF BUSINESS

The accompanying unaudited interim condensed consolidated financial statements reflect the consolidated operations of Theragenics Corporation and its wholly-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The terms “Company”, “we”, “us”, or “our” mean Theragenics Corporation and all entities included in our consolidated financial statements. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and disclosures normally included in our annual consolidated financial statements.

To prepare financial statements in accordance with GAAP, we must make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and the related disclosure of contingent assets and liabilities at the date of the financial statements. Actual amounts may differ from these estimated amounts. In our opinion, these interim financial statements include all adjustments (including normal recurring accruals) considered necessary for a fair presentation.

Our consolidated results of operations for the interim periods presented herein are not necessarily indicative of the results that may be expected for a full year. These interim financial statements and notes should be read in conjunction with our audited consolidated financial statements and notes for the year ended December 31, 2011 included in the Form 10-K Annual Report that we filed with the SEC.

We are a medical device company serving the surgical products and cancer treatment markets, operating in two business segments. Our surgical products business consists of wound closure, vascular access, and specialty needle products. Wound closure includes sutures, needles, and other surgical products. Vascular access includes introducers, guidewires, and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle based products. Our surgical products segment serves a number of markets and applications, including among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Our brachytherapy business manufactures, markets and distributes “seeds” used primarily in the minimally invasive treatment of localized prostate cancer. Our brachytherapy product line includes our palladium-103 TheraSeed® device, our iodine-125 based devices and other related products and services.

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2012

Dec. 31, 2011

CURRENT ASSETS

Cash and cash equivalents

$ 26,819

$ 29,553

Marketable securities

11,513

11,625

Trade accounts receivable, less allowance of $943 in 2012 and $2,757 in 2011

11,575

11,375

Inventories, net

17,204

15,771

Deferred income tax asset - current

1,085

2,028

Refundable income taxes

401

Prepaid expenses and other current assets

959

985

TOTAL CURRENT ASSETS

69,155

71,738

Property and equipment, net

34,139

34,519

Intangible assets, net

17,299

9,459

Deferred income tax asset - long-term

283

Other assets

102

TOTAL ASSETS

120,958

115,818

CURRENT LIABILITIES

Accounts payable

2,399

1,816

Accrued salaries, wages and payroll taxes

1,814

2,861

Short-term borrowings

22,833

23,667

Earn-out payable - current

3,338

Income taxes payable

513

Other current liabilities

1,707

1,104

TOTAL CURRENT LIABILITIES

32,604

29,448

Earn-out payable - long-term

1,540

Deferred income taxes

1,043

Asset retirement obligations

823

807

Other long-term liabilities

666

398

TOTAL LIABILITIES

35,633

31,696

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY

Common stock, authorized 100,000 shares of $0.01 par value, issued and outstanding 34,642 in 2012 and 33,991 in 2011

346

340

Additional paid-in capital

74,912

74,705

Retained earnings

10,027

9,093

Accumulated other comprehensive gain (loss)

(16)

TOTAL SHAREHOLDERS' EQUITY

85,325

84,122

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$ 120,958

$ 115,818

Document and Entity Information

3 Months Ended

Mar. 31, 2012

May 07, 2012

Document Type

10-Q

Amendment Flag

false

Document Period End Date

Mar. 31, 2012

Document Fiscal Year Focus

2012

Document Fiscal Period Focus

Trading Symbol

TGX

Entity Registrant Name

THERAGENICS CORP

Entity Central Index Key

0000795551

Current Fiscal Year End Date

--12-31

Entity Filer Category

Smaller Reporting Company

Entity Common Stock, Shares Outstanding

34,654,901

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Per Share data, unless otherwise specified

Mar. 31, 2012

Dec. 31, 2011

Trade accounts receivable, allowance

$ 943

$ 2,757

Common stock, authorized

100,000

Common stock, par value

$ 0.01

Common stock, issued

34,642

33,991

Common stock, outstanding

34,642

33,991

DISTRIBUTION AGREEMENTS AND MAJOR CUSTOMERS

3 Months Ended

Mar. 31, 2012

DISTRIBUTION AGREEMENTS AND MAJOR CUSTOMERS

NOTE F - DISTRIBUTION AGREEMENTS AND MAJOR CUSTOMERS

Brachytherapy Seed Distribution Agreements

Our brachytherapy seed business sells our TheraSeed® device directly to healthcare providers and to third-party distributors. Under our third-party distribution agreements, we are the exclusive palladium-103 seed supplier for the treatment of prostate cancer for each distributor, and each distributor has the non-exclusive right to sell TheraSeed® in the U.S. and Canada. Certain agreements also provide distributors with rights to distribute TheraSeed® for the treatment of solid localized tumors other than prostate and with rights to distribute to certain locations outside of North America. Such applications (non-prostate and outside of North America) have not been material. Our principal non-exclusive distribution agreement is with C. R. Bard (“Bard”). Our agreement with Bard (the “Bard Agreement”) provides for automatic one year extensions of the term, unless either party gives notice of its intent not to renew at least twelve months prior to the end of the current term. The current term expires December 31, 2013 and will be automatically extended for one additional year unless either party gives notice of its intent not to extend by December 31, 2012.

Major Customers

Sales to Bard under the Bard Agreement represented approximately 29% of total brachytherapy seed segment revenue for the quarters ended March 31, 2012 and 2011, respectively. Our surgical products segment also sells to Bard. Total consolidated sales to Bard, including sales in our brachytherapy seed segment and our surgical products segment, represented approximately 9% and 11% of consolidated revenue for the quarters ended March 31, 2012 and March 31, 2011, respectively.

Accounts receivable from Bard represented approximately 21% of brachytherapy accounts receivable and less than 10% of consolidated accounts receivable at March 31, 2012. At December 31, 2011, accounts receivable from Bard under the Bard Agreement represented approximately 19% of brachytherapy accounts receivable and less than 10% of consolidated accounts receivable.

Core Oncology became an additional non-exclusive distributor of TheraSeed® in January 2010. In February 2011, we terminated our agreement with Core due to Core’s failure to satisfy its financial obligation to us in accordance with the contractual terms of the agreement. Core had been attempting to become current with amounts due to us. However, litigation filed against Core by a third party in January 2011 created what we viewed as an unacceptable level of uncertainty surrounding Core’s ability to satisfy their financial obligations to us for both current and ongoing sales. Subsequent to termination of the agreement, we continued to supply TheraSeed® to Core on a prepaid basis. Sales to Core in our brachytherapy segment totaled approximately 11% of total brachytherapy seed segment revenue in the first quarter of 2011. In the latter half of 2011, certain customers who previously purchased TheraSeed® through Core began purchasing either from us on a direct basis or through one of our other TheraSeed® distributors. At December 31, 2011 an allowance for doubtful accounts was established for the entire amount of accounts receivable due from Core, which totaled $2.2 million (the “Core Accounts Receivable”). On February 17, 2012, we acquired Core’s prostate brachytherapy customer base. See Note B. In connection with the acquisition of the Core customer base on February 17, 2012, we released Core from all claims existing at that date, including the Core Accounts Receivable. Accordingly, the $2.2 million for which an allowance had been established was written off as uncollectible in the first quarter of 2012.

One customer totaled 10% of surgical products accounts receivable at March 31, 2012.

CONTINGENCIES

3 Months Ended

Mar. 31, 2012

CONTINGENCIES

NOTE I – CONTINGENCIES

Litigation and claims

From time to time we may be a party to claims that arise in the ordinary course of business, none of which, in our view, is expected to have a material adverse effect on our consolidated financial position or our results of operations.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified

3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

CASH FLOWS FROM OPERATING ACTIVITIES

Net earnings

$ 934

$ 458

Adjustments to reconcile net earnings to net cash provided by operating activities:

Depreciation and amortization

1,983

1,780

Deferred income taxes

(383)

(182)

Provision for allowances

269

Share-based compensation

196

171

Change in fair value of interest rate swaps

(28)

(33)

Decommissioning retirement liability

(Gain) loss on sale of marketable securities

(1)

Changes in assets and liabilities, net of asset acquisition:

Accounts receivable

(246)

(1,211)

Inventories

(1,134)

(646)

Prepaid expenses and other current assets

Trade accounts payable

583

(175)

Accrued salaries, wages and payroll taxes

(1,047)

(660)

Income taxes payable/refundable

914

461

Other current liabilities

319

Other

230

(31)

Net cash provided by operating activities

2,383

287

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases and construction of property and equipment

(329)

(696)

Cash paid for acquisition of Core Oncology customer base

(4,086)

Proceeds from sale of property and equipment

Purchases of marketable securities

(1,708)

(4,176)

Maturities of marketable securities

1,634

1,310

Proceeds from sales of marketable securities

189

Net cash used by investing activities

(4,300)

(3,557)

CASH FLOWS FROM FINANCING ACTIVITIES

Repayment of borrowings

(834)

Employee stock purchase plan

Retirement of common stock

(14)

Net cash used by financing activities

(817)

(834)

NET DECREASE IN CASH AND CASH EQUIVALENTS

(2,734)

(4,104)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

29,553

29,674

CASH AND CASH EQUIVALENTS AT END OF PERIOD

26,819

25,570

SUPPLEMENTARY CASH FLOW DISCLOSURE:

Interest paid

182

212

Income taxes (received) paid, net

(15)

NON-CASH INVESTING AND FINANCING ACTIVITIES:

Assets acquired from the Core transaction

5,241

Liability for property and equipment acquired

$ 39

$ 95

SHARE-BASED COMPENSATION

3 Months Ended

Mar. 31, 2012

SHARE-BASED COMPENSATION

NOTE E – SHARE-BASED COMPENSATION

During the quarter ended March 31, 2012, we granted 635,000 shares of restricted stock (with a grant date fair value of $1.56 per share based on the market price of the underlying common stock at the grant date) to executive officers in connection with long-term incentive compensation programs. The restricted stock vests ratably over four years.

Compensation cost for the restricted stock is being recorded over the requisite service period of the grants. As of March 31, 2012, there was approximately $948,000 of unrecognized compensation cost related to restricted stock granted in the first quarter of 2012 which is expected to be recognized over a weighted average period of 2.5 years.

Delaware		58-1528626
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

5203 Bristol Industrial Way
Buford, Georgia		30518
(Address of principal executive offices)		(Zip Code)

	Page No.
PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Condensed Consolidated Statements of Comprehensive Earnings for the quarters ended March 31, 2012 and 2011	3

Condensed Consolidated Balance Sheets – March 31, 2012 and December 31, 2011	4

Condensed Consolidated Statements of Cash Flows for the quarters ended March 31, 2012 and 2011	5

Notes to Condensed Consolidated Financial Statements	6

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	13

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	21

ITEM 4. CONTROLS AND PROCEDURES	21

PART II. OTHER INFORMATION	22

ITEM 1. LEGAL PROCEEDINGS	22

ITEM 1A. RISK FACTORS	22

ITEM 6. EXHIBITS	23

SIGNATURES	24

	Amount		Estimated Life
Inventory	$	274
Developed technology equipment		324	7 years
Intangibles
Customer relationships		7,857	7 years
Non-compete agreements		681	5 years
Developed technology		191	1.5 years
		8,729	6.7 years

Total estimated cost of assets acquired	$	9,327

	Quarter Ended March 31
	2012			2011
Balance, beginning of the period	$	7,667		$	11,000
New contracts		—			—
Matured contracts		(834	)		(834	)
Balance, end of the period	$	6,833		$	10,166

	Quarter Ended March 31,
	2012			2011
REVENUE
Product sales	$	20,979		$	19,738
License and fee income		604			515
		21,583			20,253
COST OF SALES		12,974			12,286
GROSS PROFIT		8,609			7,967

OPERATING EXPENSES
Selling, general and administrative		5,901			5,847
Amortization of purchased intangibles		855			698
Research and development		277			535
Loss on disposal of assets		—			1
		7,033			7,081

EARNINGS FROM OPERATIONS		1,576			886

OTHER INCOME (EXPENSE)
Interest income		38			40
Interest expense		(164	)		(177	)
Other		1			1
		(125	)		(136	)

EARNINGS BEFORE INCOME TAXES		1,451			750

Income tax expense		517			292

NET EARNINGS	$	934		$	458

EARNINGS PER SHARE:
Basic	$	0.03		$	0.01
Diluted	$	0.03		$	0.01

WEIGHTED AVERAGE SHARES
Basic		33,533			33,338
Diluted		33,941			33,645

COMPREHENSIVE EARNINGS
Net earnings	$	934		$	458
Other comprehensive earnings, net of taxes
Reclassification adjustment for (gain) loss included in net earnings		(1	)		1
Unrealized gains on securities arising during the period		57			5
Total other comprehensive earnings		56			6
Total comprehensive earnings	$	990		$	464


	March 31, 2012 (Unaudited)		December 31, 2011
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	26,819	$	29,553
Marketable securities		11,513		11,625
Trade accounts receivable, less allowance of $943 in 2012 and $2,757 in 2011		11,575		11,375
Inventories, net		17,204		15,771
Deferred income tax asset - current		1,085		2,028
Refundable income taxes		—		401
Prepaid expenses and other current assets		959		985
TOTAL CURRENT ASSETS		69,155		71,738

Property and equipment, net		34,139		34,519
Intangible assets, net		17,299		9,459
Deferred income tax asset – long-term		283		—
Other assets		82		102

TOTAL ASSETS	$	120,958	$	115,818

LIABILITIES & SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES
Accounts payable	$	2,399	$	1,816
Accrued salaries, wages and payroll taxes		1,814		2,861
Short-term borrowings		22,833		23,667
Earn-out payable - current		3,338		—
Income taxes payable		513		—
Other current liabilities		1,707		1,104
TOTAL CURRENT LIABILITIES		32,604		29,448

Earn-out payable – long-term		1,540		—
Deferred income taxes		—		1,043
Asset retirement obligations		823		807
Other long-term liabilities		666		398
TOTAL LIABILITIES		35,633		31,696

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY
Common stock, authorized 100,000 shares of $0.01 par value, issued and
outstanding 34,642 in 2012 and 33,991 in 2011		346		340
Additional paid-in capital		74,912		74,705
Retained earnings		10,027		9,093
Accumulated other comprehensive gain (loss)		40		(16	)
TOTAL SHAREHOLDERS’ EQUITY		85,325		84,122

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	120,958	$	115,818

	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Total
March 31, 2012
Money market funds	$	8,671	$	—		$	—	$	8,671
Marketable securities		11,513		—			—		11,513
Total assets	$	20,184	$	—		$	—	$	20,184

Interest rate swaps liability	$	—	$	(29	)	$	—	$	(29	)

December 31, 2011
Money market funds	$	8,483	$	—		$	—	$	8,483
Marketable securities		11,625		—			—		11,625
Total assets	$	20,108	$	—		$	—	$	20,108

Interest rate swaps liability	$	—	$	(57	)	$	—	$	(57	)

	March 31, 2012			December 31, 2011
Raw materials	$	8,089		$	7,756
Work in process		4,796			3,724
Finished goods		3,978			3,988
Spare parts and supplies		933			920
		17,796			16,388
Allowance for obsolete inventory		(592	)		(617	)
Inventories, net	$	17,204		$	15,771

	March 31,			December 31,
	2012			2011

Identifiable assets
Surgical products	$	72,094		$	72,475
Brachytherapy seed		68,800			60,791
Corporate investment in subsidiaries		111,439			111,439
Intersegment eliminations		(131,375	)		(128,887	)
	$	120,958		$	115,818
Intangible assets
Surgical products	$	8,705		$	9,404
Brachytherapy seed		8,594			55
	$	17,299		$	9,459

	Quarter Ended March 31,						Increase
	2012			2011			$			%
Revenues by segment:
Surgical products
Product sales	$	15,483		$	14,381		$	1,102			8	%
License and fee income		11			11			—			—
Total surgical products		15,494			14,392			1,102			8	%

Brachytherapy seed
Product sales		5,727			5,449			278			5	%
License and fee income		593			504			89			18	%
Total brachytherapy seed		6,320			5,953			367			6	%

Intersegment eliminations		(231	)		(92	)		(139	)		(151	%)

Consolidated
Product sales		20,979			19,738			1,241			6	%
License and fee income		604			515			89			17	%
Total consolidated	$	21,583		$	20,253		$	1,330			7	%

Exhibit No.		Title

2.1		Asset Purchase Agreement by and Between Theragenics Corporation and Core Oncology, Inc. (Confidential treatment has been requested from the SEC for certain portions of this exhibit)

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted to Section 906 of the Sarbanes-Oxley Act of 2002.

101		Interactive Data Files providing financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 in XBRL (eXtensible Business Reporting Language). Pursuant to Regulation 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and are otherwise not subject to liability.

	REGISTRANT:

	THERAGENICS CORPORATION

Date: May 14, 2012	By:	/s/ M. Christine Jacobs
		M. Christine Jacobs
		Chief Executive Officer

Date: May 14, 2012	By:	/s/ Francis J. Tarallo
		Francis J. Tarallo
		Chief Financial Officer

			Page

1.	DEFINITIONS		1
	1.1.	Definitions	1
	1.2.	Usage	2

2.	PURCHASE AND SALE OF ASSETS AND ASSIGNMENT AND ASSUMPTION OF LIABILITIES		2
	2.1.	Purchase and Sale of Acquired Assets; Assumption of Assumed Liabilities	2
	2.2.	Purchase Price	3
	2.3.	Manner of Payment of Closing Cash Payment and Earn-Out Payments	4
	2.4.	Time and Place of Closing	5
	2.5.	Deliveries at the Closing	5
	2.6.	Allocation of Purchase Price	5
	2.7.	Proration of Ad Valorem Taxes	6
	2.8.	Audit of Earn-Out Payments	6

3.	REPRESENTATIONS AND WARRANTIES OF SELLER		7
	3.1.	Organization and Good Standing	7
	3.2.	Authority; No Conflict	7
	3.3.	Business Records	8
	3.4.	Title to Properties; Security Interests	8
	3.5.	Condition and Sufficiency of Assets	8
	3.6.	Taxes	8
	3.7.	Financial Statements	9
	3.8.	Compliance with Legal Requirements; Governmental Authorizations	9
	3.9.	Legal Proceedings; Orders	10
	3.10.	Financial Condition	10
	3.11.	Absence of Certain Changes and Events	10
	3.12.	Contracts; No Defaults	11
	3.13.	Customers and Suppliers	12
	3.14.	Environmental Matters	12
	3.15.	[Reserved]	12
	3.16.	Intellectual Property	13
	3.17.	Certain Payments	14
	3.18.	Relationships with Related Persons	14
	3.19.	Product Warranty and Liability	14
	3.20.	Brokers or Finders	14

4.	REPRESENTATIONS AND WARRANTIES OF PURCHASER		15
	4.1.	Organization and Good Standing	15
	4.2.	Authority; No Conflict	15
	4.3.	Certain Proceedings	15
	4.4.	Brokers or Finders	15

5.	PRE-CLOSING COVENANTS		16
	5.1.	Access and Investigation	16
	5.2.	Operation of the Business	16
	5.3.	Negative Covenant	16
	5.4.	Required Approvals	16
	5.5.	Release of Security Interests	17
	5.6.	No Negotiation	17
	5.7.	Best Efforts	17
	5.8.	Assignment of Interests in Acquired Assets	17
	5.9.	Notification of Certain Events	18
	5.10.	Supplements to Disclosure Schedules	18
	5.11.	Employees	18
	5.12.	Meetings with Customers and Suppliers	19

6.	POST-CLOSING COVENANTS		19
	6.1.	Litigation Support	19
	6.2.	Transition	19
	6.3.	Tax Matters	19
	6.4.	Restrictive Covenants	20
	6.5.	Release	22
	6.6.	Sufficiency of Working Capital	23
	6.7.	Deferred Purchased Intellectual Property	23

7.	CONDITIONS PRECEDENT TO PURCHASER’S OBLIGATION TO CLOSE		24
	7.1.	Accuracy of Representations; Performance by Seller	24
	7.2.	Additional Documents	24
	7.3.	Release of Security Interests; Subordination and Consent to Transfer	25
	7.4.	No Proceedings	25
	7.5.	No Claim Regarding Ownership or Sale Proceeds	26
	7.6.	No Material Adverse Effect	26
	7.7.	Required Consents	26
	7.8.	No Prohibition	26
	7.9.	Due Diligence	26
	7.10.	Assignment of Contracts	26

8.	CONDITIONS PRECEDENT TO THE SELLER’S OBLIGATION TO CLOSE		27
	8.1.	Accuracy of Representations; Purchaser’s Performance	27
	8.2.	Additional Documents	27
	8.3.	No Injunction	27

9.	TERMINATION		27
	9.1.	Termination Events	27
	9.2.	Effect of Termination	28

10.	INDEMNIFICATION; REMEDIES		28
	10.1.	Survival	28
	10.2.	Indemnification and Payment of Damages by Seller	29

	10.3.	Time Limitations; Limitation on Amount	29
	10.4.	Procedure for Indemnification – Third Party Claims	30
	10.5.	Procedure for Indemnification – Other Claims	31
	10.6.	Holdback; Satisfaction of Losses	31
	10.7.	Tax Treatment	32

11.	GENERAL PROVISIONS		33
	11.1.	Expenses	33
	11.2.	Public Announcements	33
	11.3.	Notices	33
	11.4.	Further Assurances	34
	11.5.	Waiver	34
	11.6.	Entire Agreement and Modification	35
	11.7.	Disclosure Schedules	35
	11.8.	Assignments, Successors, and No Third-Party Rights	35
	11.9.	Severability	36
	11.10.	Time of Essence	36
	11.11.	Governing Law; Consent to Jurisdiction; Waiver of Jury Trial	36
	11.12.	Specific Performance	36
	11.13.	No Strict Construction	36
	11.14.	Use of Name	37
	11.15.	Appendices, Exhibits and Schedules	37
	11.16.	Counterparts	37
	11.17.	Acquired Equipment/Additional Equipment	37

Annexes, Schedules and Exhibits

Annex I	Definitions
Annex II	Example of Mechanics of Payments Under the Agreement

Disclosure Schedules:
Schedule 3.2	Exceptions to representations in Section 3.2 (Authority; No Conflict)
Schedule 3.5	Acquired Inventory, Parts and Components; Acquired Inventory, Finished Goods; Acquired Equipment
Schedule 3.8	Exceptions to representations in Section 3.8 (Compliance with Law; list of Governmental Authorizations)
Schedule 3.9	Legal Proceedings
Schedule 3.11	Exceptions to representations in Section 3.11 (Absence of Changes/Events)
Schedule 3.12(a)	Material Contracts
Schedule 3.12(c)	Acquired Contracts
Schedule 3.13(a)	Customer List
Schedule 3.13(b)	Supplier List
Schedule 3.16 Acquired Intellectual Property, including separate lists of Closing Purchased Intellectual Property, Deferred Purchased Intellectual Property, and Nonexclusive Intellectual Property

Schedule 3.19	Warranties and Liabilities
Schedule 3.20	Brokers or Finders
Schedule 5.4	Required Approvals

Exhibit A	Temporary Manufacturing and Supply Agreement
Exhibit B	Bill of Sale
Exhibit C	Assignment and Assumption Agreement

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods referred to in the Report.